Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention

Bernhard Biersack
Organic Chemistry Laboratory, University of Bayreuth, Universitätsstraße 30, 95447 Bayreuth, Germany

ARTICLE INFO

Article history:
Received 16 June 2016
Received in revised form
20 July 2016
Accepted 20 July 2016
Available online 27 July 2016

Keywords:
MicroRNA
Polyphenols
Terpenes
Anticancer drugs

ABSTRACT

The epigenetic regulation of cancer cells by small non-coding RNA molecules, the microRNAs (miRNAs), has raised particular interest in the field of oncology. These miRNAs play crucial roles concerning pathogenic properties of cancer cells and the sensitivity of cancer cells towards anticancer drugs. Certain miRNAs are responsible for an enhanced activity of drugs, while others lead to the formation of tumor resistance. In addition, miRNAs regulate survival and proliferation of cancer cells, in particular of cancer stem-like cells (CSCs), that are especially drug-resistant and, thus, cause tumor relapse in many cases. Various small molecule compounds were discovered that target miRNAs that are known to modulate tumor aggressiveness and drug resistance. This review comprises the effects of naturally occurring small molecules (phenolic compounds and terpenoids) on miRNAs involved in cancer diseases.

© 2016 The Author. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

The investigation of the role of microRNAs (miRNAs), short and highly conserved non-coding RNAs of 22-23 nucleotides, for various diseases has risen distinctly over the last years. At the moment, there are more than two thousand miRNAs that regulate about one-third of all human genes [1]. MiRNAs are involved in the regulation of processes such as proliferation, apoptosis, and differentiation of cells [2]. Concerning cancer, miRNAs can exert either tumor suppressor or oncogenic activities [1]. Characteristic patterns of miRNA expression were observed from certain tumor tissues and, thus, miRNAs can also feature valuable diagnostic and prognostic factors [3–7]. In addition, miRNAs play a crucial role for the formation and survival of cancer stem-like cells (CSCs) [8,9]. Epithelial-to-mesenchymal transition (EMT) of cancer cells is regulated by miRNAs which, thus, play a crucial role for the formation of metastases [10,11].

Mature miRNAs bind to target messenger RNAs (mRNAs) and suppress their translation [12]. The biosynthesis of miRNAs generally starts with the transcription of miRNA genes by RNA polymerase II thus generating precursor miRNAs (pri-miRNAs) of several kilobases [13]. Then, the microprocessor complex including the RNase III enzyme Drosha and DGR8 processes these pri-miRNAs into pre-miRNAs of 65–70 nucleotides that form hairpin structures in the nucleus [13,14]. These pre-miRNAs are transported from the nucleus to the cytoplasm via the transporter Exportin-5 in a Ran-GTPase dependent way [15–17]. In the cytoplasm, the pre-miRNAs are processed by the Dicer-TRBP (tar binding protein) complex leading to double-stranded RNAs which comprise the mature miRNA and its complementary strand [11,15–17]. After separation from the complementary strand, the mature miRNA binds to the AGO2 (Argonaut 2) protein which recruits further proteins forming miRISC (miRNA–induced silencing complex) [18]. MiRISC is able to bind to target mRNAs leading either to a block of translation or to the degradation of the target mRNAs by miRISC. The seed region of the miRNA (nucleotides 2–7 of the 5′-end of the miRNA) binds to the complementary 3′-untranslated regions (UTR) of target mRNAs leading to inhibition of mRNA translation [9,19,20]. Aside negative regulation of mRNA translation, certain miRNAs were also found to promote mRNA translation by recruitment of
proteins to the AU-rich elements of mRNA or by interference with translation inhibiting proteins [21,22].

It was observed that single miRNAs can target various genes while dysregulation of tumor suppressor or oncogenic miRNAs can be found in many human cancer types [23,24]. Thus, miRNAs with effects on carcinogenesis, cell proliferation and differentiation, apoptosis, and on the formation of metastasis and drug resistance feature a valuable target for the design of potent anticancer drugs [25–27]. The application of accurate miRNAs (either as mimics or as antagonoms) in therapy is limited due to low cell permeability and the facile degradation of RNA molecules, however, liposomal formulations such as MRX34 of the tumor suppressor miRNA-34a (Mirnax Therapeutics) revealed sufficient stability and cell delivery of the anti-cancer active miRNA leading to the initiation of phase I clinical trials with MRX34 [18]. Nevertheless, dietary factors and natural products are easily obtained from natural sources and, thus, usually provide a rich supply of low-cost, safe and easily available miRNA-modulatory drug candidates. Suitable anticancer drugs from this pool of anticancer active dietary factors and natural products should either inhibit the activity of oncogenic miRNAs or promote the activity of tumor suppressor miRNAs. This review provides an overview of anticancer active natural products (phenols, terpenes) and their manifold interactions with miRNAs involved in cancer diseases.

2. Classification of miRNAs as tumor suppressors or oncogenes

2.1. Tumor suppressing miRNAs

Let-7 features one of the most prominent tumor suppressing miRNA families, and let-7 miRNAs are distinctly downregulated or even completely lost in certain cancer types [28]. A connection between let-7 and K-Ras mutation was observed and restored let-7 led to significant tumor growth inhibition in K-Ras lung cancer models [29,30]. Downregulation of let-7 was shown for breast, colon, lung and pancreas carcinomas and correlated with worse prognosis in lung cancer patients [28,29,31,32]. The first identified tumor suppressing microRNAs were miR-15 and miR-16 in CLL (chronic lymphocytic leukemia) cells [33]. Increased levels of miR-15a and miR-16-1 induced apoptosis while high levels of the anti-apoptotic Bcl-2 protein led to reduced concentrations of miR-15a and miR-16-1 [34]. Restored miR-16 exhibited growth inhibition in prostate cancer cells [35]. In addition, miR-15 and miR-16 sensitized multidrug-resistant gastric cancer cells to chemotherapy [36]. MiR-34 is another important tumor suppressor that attacks tumor-initiating pancreas cancer cells and leads to apoptosis, cell-cycle arrest, and anti-angiogenesis [37–39]. Singh and coworkers disclosed the tumor suppressing effects of miR-150 in pancreas cancer cells via repression of the oncoprotein MUC4 [40]. In mixed lineage leukemia cells (MLL) miR-495 was suppressed and restoration of this miRNA led to inhibition of leukemia cell growth both in vitro and in vivo [41]. Further examples of tumor suppressor miRNAs with effects on hepatoma and pancreas cancer feature miR-203 and miR-451 [42–45]. Further to this, there are several miRNAs which explicitly suppress metastasis formation. In breast cancer models, the expression of miRNAs such as miR-126, miR-206, and miR-335 reduced bone and lung metastasis formation [46]. MiR-126 also inhibited the migration and invasion of prostate cancer cells [47]. In lung cancer, miR-126 and miR-183 likewise blocked metastasis formation [48,49].

2.2. Oncogenic miRNAs

Several oncogenic miRNAs (OncomiRs) were identified which are overexpressed in many cancer types due to gene amplification or upregulated miRNA gene expression [50]. These miRNAs either block tumor suppressor gene expression or regulate epigenetically the expression of pathogenic genes (oncogenes) [51]. MiR-21 features a prominent example of an oncogenic miRNA which inhibited apoptosis in glioblastoma cells [52]. A connection with the anti-apoptotic Bcl-2 protein was observed in breast cancer cells and down-regulation of Bcl-2 occurred after suppression of miR-21 [53]. In pancreas cancer cells, oncogenic miR-27a was overexpressed and targeted the tumor suppressor Sprouty2 [54]. High levels of miR-424-5p in pancreas cancer cells blocked apoptosis and increased cell proliferation via SOCS6 suppression [55]. Another important OncomiR is miR-155 that promoted the proliferation of triple-negative breast cancers and represents a marker of bad prognosis for pancreas cancer patients [56,57]. Various cancers revealed an overexpression of oncogenic miR-155 [57–59]. The miR-17-92 cluster plays an oncogenic role in various tumor diseases and upregulation of the miR-17-92 cluster correlated with increased tumor formation and angiogenesis [60–62]. B-cell lymphoma models exhibited stronger c-myc-dependent tumor growth upon expression of the miR-17-92 cluster [63]. The miRNA miR-10b was upregulated in breast cancer cells and increased migration, invasion and metastasis formation of breast cancer cells [64]. In addition, miR-10b was a marker for bad prognosis in primary breast carcinoma [64]. The miRNAs miR-373 and miR-520c enhanced the migration and invasion of cancer cells by affection of CD44 expression [65]. The metastatic potential of prostate cancer cells was likewise increased by miR-373 and miR-520c [66]. Breast cancer cells were able to form metastases in mice because of miR-373 and miR-520c overexpression [65]. In addition, clinical samples of breast cancer metastases revealed high miR-373 levels [65]. Various miRNAs contribute to drug resistance in cancer cells. Overexpression of miR-221 and miR-222 led to tamoxifen resistance in breast cancer cells and to TRAIL (tumor necrotic factor-related apoptosis-inducing ligand) resistance in non-small cell lung cancer cells (NSCLC) [67,68]. The cisplatin resistance of ovarian cancer cells correlated with increased miR-214 levels targeting PTEN [69]. The effects of dietary and natural phenolic compounds and terpenoids on these miRNAs as well as on further specific miRNA examples are discussed in the following chapter. A short list of microRNAs with significant oncogenic or tumor suppressing activities in the four main solid tumor diseases of Western peoples [i.e., lung cancer, colorectal cancer, prostate cancer (men), and breast cancer (women)] is given in Table 1 [70–73].

3. Dietary compounds and natural products (phenols and terpenoids) with effects on miRNA expression and activity

3.1. Phenolic compounds

3.1.1. Curcumin and curcuminoinds

Curcumin is a phytochemical compound isolated from the rizomes of turmeric (Curcuma longa, haldi) [74]. Turmeric has been applied as a spice for Asian dishes and as a drug in traditional Indian (Ayurveda) and Chinese (TCM) medicine for centuries. Structurally, curcumin is an α,β-unsaturated β-diketone (diferuloylmethane) that shows keto-enol-tautomerism (Fig. 1) [74]. Curcumin has been thoroughly investigated as an anti-inflammatory and anticancer agent and has already undergone several clinical trials [75]. Curcumin features a pleiotropic agent and targets NF-κB (nuclear factor-κB), Akt (protein kinase B) signaling, Wnt signaling, STAT-3 (signal transducers and activators of transcription-3), COX-2 (cyclooxygenase-2), proinflammatory MMP (matrix metalloproteinase), etc. [74]. It also exhibited various effects on miRNAs, which contribute to its sound anticancer activity [75]. In MCF-7 breast cancer cells, curcumin induced the expression
of the tumor suppressors miR-15a and miR-16 and, thus, suppressed the anti-apoptotic Bcl-2 protein [76]. These miRNAs were also upregulated in K-562 and HL-60 leukemia cells upon treatment with curcumin and WT1 (Wilm's Tumor 1) was identified as a target of miR-15a and miR-16 here [77]. Curcumin also activated the promoter of the miR-203 tumor suppressor gene (by hypomethylation) leading to the overexpression of miR-203 and curcumin-treated bladder cancer cells showed reduced levels of miR-203 targets, the protein kinases Akt and Src, as well as increased apoptosis and decreased proliferation and invasion [78]. Curcumin enhanced the expression of miR-22 in Y79 retinoblastoma cells leading to increased cell growth and migration inhibition via the miR-22 target ErbB3 [79]. In triple-negative breast cancer cells (MDA-MB-231), curcumin induced overexpression of miR-181b leading to inhibition of the formation of MMPs (matrix metalloproteinases) and downregulation of the chemokines CXCL1 and CXCL2 (chemokine C-X-C motif ligand) [80]. These events led to reduced invasion and metastasis formation [76]. Overexpression of miR-9 was observed in ovarian cancer cells (SKOV3) after treatment with curcumin leading to enhanced cytotoxicity [81]. A curcumin diet given to mice suffering from B7/8H1 murine melanoma revealed distinct tumor regression and a huge overexpression of the murine miRNA mmu-miR-205-5p (135-fold higher expression) in the tumors of curcumin-fed mice [82]. The miRNA mmu-miR-205-5p reversed EMT and was downregulated in metastatic melanomas [83,84]. Curcumin blocked pancreatic cancer cell growth and invasion via induction of miR-7 expression associated with suppression of SET8 expression [85]. In NSCLC cells, curcumin-induced apoptosis was correlated with the curcumin-mediated upregulation of the tumor suppressors miR-192-5p and miR-215 in a p53-dependent way leading to down-regulation of XIAP (X-linked inhibitor of apoptosis) [86]. A major drawback of curcumin is its low bioavailability and aqueous solubility, thus, dendrosomal curcumin formulations were prepared which exhibited improved properties [87]. Indeed, dendrosomal curcumin increased the expression of miR-145 in glioblastoma cells (U87MG) leading to tumor cell growth inhibition via miR-145-mediated suppression of genes involved in the formation of cancer stemness properties such as Nanog, OCT4A (octamer binding protein 4), OCT4B1, and SOX-2 (SRY-box 2) [87]. Dendrosomal curcumin also induced miR-29a and miR-185 expression in hepatocellular carcinoma (HCC) cells associated with suppression of the DNA-methylases DNMT1, DNMT3A and DNMT3B leading to hypomethylation of the MEG3 promoter and increased expression of the tumor suppressing long non-coding RNA MEG3 [88].

Curcumin reduced the expression of the oncogenic miR-21 in colon cancer cells (RKO, HCT-116) leading to reduced tumor growth and metastasis formation by enhanced expression of the miR-21 target PDCD4 (programmed cell death protein 4) [89]. In addition, curcumin downregulated miR-17-5p, miR-20a, and miR-27a (targeting SP repressors, zinc finger and BTB-domain proteins such as ZBTB4/10) in colon cancer cells (RKO, SW480) leading to increased growth inhibition [90]. MiR-21 was suppressed in A549 NSCLC cells after treatment with curcumin as well, followed by activation of the miR-21 target PTEN (phosphatase and tensin homolog) [91]. In human esophageal cancer cells (TE-7), curcumin induced apoptosis and cell cycle arrest via suppression of miR-21 and miR-34a, while the tumor suppressor let-7 was induced by curcumin in these cancer cells [92]. In addition, curcumin successfully inhibited lung cancer cell proliferation (both A549 wt and A549/DDP multidrug resistant cells) and induced apoptosis by downregulation of oncogenic miR-186* which targets caspase-10 [93,94]. Interestingly, there’s conflicting data about the role of miR-200 concerning curcumin treatment. In hepatoma cells (HepG2, HepG5), overexpression of miR-200a and miR-200b led to enhanced curcumin resistance via increased anti-apoptotic Bcl-2 levels and decreased pro-apoptotic Bad and Bax levels [95]. In contrast to that, gemcitabine-resistant pancreas cancer cells (MiaPaCa-E, MiaPaCa-M) showed decreased levels of miR-200b/c while after treatment with curcumin the levels of miR-200b/c were increased in these cells [96]. Modulation of miR-200c expression (upregulation) also played a role for the curcumin-induced sensitization of colon cancer cells to the approved anticancer drug 5-fluorouracil (5FU) [97]. In prostate cancer cells (PC3), curcumin suppressed oncogenic miR-208 in a dose-dependent way, and, thus, induced the expression of the cell cycle inhibitor and miR-208 target CDKNA1 leading to prostate tumor cell growth inhibition [98].

Due to the impressive biological activities of curcumin, the preparation of curcumin derivatives (curcuminoids) with improved properties has become a valuable strategy to obtain sound anticancer drugs. In particular, fluoro-derivatives of curcumin have shown improved anticancer activity when compared with their parent drug curcumin. A remarkable semisynthetic curcuminoid is CDF, the Knoevenagel condensation product of curcumin and 3,4-difluorobenzaldehyde (Fig. 1) [99]. CDF exhibited much higher anticancer activity than curcumin and accumulated in pancreas...
tissue making it an interesting drug candidate for pancreas cancer diseases [96,98,100]. CDF was able to re-sensitize drug-resistant pancreatic cancer cells to gemcitabine and enhanced the expression of tumor suppressor miRNAs (miR-200) while it reduced the levels of oncogenic miR-21 leading to PTEN upregulation [96,101]. Under hypoxic conditions, prostate cancer cells upregulate miR-21, however, after treatment with CDF miR-21 expression and tumor growth was efficiently reduced [102]. The hypoxia-mediated aggressiveness of pancreas cancer cells was also related to increased expression of miR-21 and miR-210, and treatment with CDF significantly reduced the expression of miR-21 and miR-210 in vitro and in vivo [103]. In addition, CDF reduced miR-21 levels and restored PTEN expression in colon cancer cells, while expression of the tumor suppressor miR-34 was induced by CDF in colon cancer [104,105]. CDF was also able to modulate miRNAs targeting matrix metalloproteinases (MMPs) which play a crucial role for the invasion competence of cancers. MiR-874 was upregulated by CDF in non-small cell lung cancer cells which led to MMP-2 inhibition [106]. Oncogenic miR-221 was downregulated by CDF in pancreas cancer cells as well, and CDF inhibited proliferation and migration of pancreas cancer cells by upregulation of p27, p57, PTEN, and PUMA (p53 upregulated modulator of apoptosis) [107]. In addition, CDF upregulated let-7 and miR-101 which suppressed the histone methyltransferase EZH2 associated with reduced survival, invasion and cancer stem cell function in pancreatic cancer [108]. The tumor suppressor miR-143 was likewise induced by CDF in pancreatic cancer cells as well as the tumor suppressor miR-146a leading to suppressed EGFR (epidermal growth factor receptor) signaling and inhibition of pancreatic tumor growth [109,110].

Another interesting synthetic curcuminoid is EF24 [3,5-bis[2-fluorobenzylidene)piperidin-4-one] which is easily prepared by condensation of piperidin-4-one with two equivalents of 2-fluorobenzaldehyde (Fig. 1) [111]. EF24 exhibited distinctly stronger growth inhibition and anti-angiogenic activity than curcumin [111,112]. Hence, it is not surprising that EF24 efficiently suppressed oncogenic miR-21 in prostate cancer (DU145) and melanoma (B16) cells and upregulated the miR-21 targets PTEN and PDCD4 [112]. A recent study of EF24 in melanoma cells disclosed significant effects on miR-33b expression, and suppression of EMT (=suppression of metastasis formation) as well as HMG2 (high-mobility group AT-hook 2) inhibition were observed after treatment with EF24 associated with upregulation of miR-33b [113]. The miRNAs (both tumor suppressor and oncogenic ones) regulated by curcumin and its derivatives are presented in Table 2.

### 3.1.3. Garcinol

The phenolic natural product garcinol was isolated from the kokum tree (*Garcinia indica*) that grows in Western India [114]. Aside its application as a spice for Western Indian dishes, kokum is also applied in Ayurveda medicine for the treatment of infections and edema [115,116]. Chemically, garcinol (camboginol) is a type B polycyclic polypropenylated acylophloroglucinol (PPAP) featuring a benzophenone derivative with five isoprenyl side chains attached to the phloroglucinol core (Fig. 1) [117]. Garcinol is easily isolated from dried kokum plums, however, there’s a total synthetic procedure of garcinol and its close congeners isogarcinol available now as well [118,119]. The chemical structure of garcinol shows some similarities with curcumin (β-diketone, phenol). Garcinol has revealed significant anticancer activity by targeting NF-κB, 5-lipoxygenase (5-LOX), and STAT proteins (for a recent review see ref. [118]). In addition, garcinol is a well-documented HAT inhibitor (histone acetylase inhibitor) and, thus, plays an important role for the epigenetic regulation of gene expression including the expression of oncogenes [120]. Synergistic effects were observed from combinations of garcinol with gemcitabine in pancreas cancer cells (including gemcitabine-resistant Panc-1 cells) due to garcinol-mediated modulation of miRNAs [121]. Garcinol downregulated oncogenic miR-21 (0.56-fold), miR-495 (0.97-fold), miR-495 (1.14-fold), and miR-1977 (0.80-fold) when compared with untreated pancreas cancer cells [121]. The expression of the micro-RNAs miR-453 (4.69-fold), miR-128 (1.82-fold), miR-1280 (0.46-fold) and miR-720 (0.43-fold) was upregulated by garcinol. The combination of garcinol with gemcitabine led to downregulation of miR-196a (0.82-fold), miR-495 (1.26-fold), miR-1914 (1.85-fold), miR-605 (2.42-fold), and miR-483-3p (1.06-fold) as well as upregulation of miR-638 (0.65-fold), miR-720 (0.41-fold), miR-453 (4.78-fold) and miR-663 (0.92-fold) [121]. Further to this, in breast cancer cells (MDA-MB-231, BT-549) garcinol reverted the metastasis-related EMT mechanism to the non-invasive MET (mesenchymal-to-epithelial transition) mechanism by induction of expression of the tumor suppressor miRNAs let-7a, let-7e, let-7f, miR-200b, and miR-200c both in vitro and in vivo in breast cancer xenograft models [122]. The microRNAs regulated by garcinol are presented in Table 2.

#### 3.1.3.1. Flavanoids

The rich natural product class of the flavanoids (phenylchroman derivatives) comprises numerous bioactive compounds. In particular, soy isoflavones (3-phenylchromen derivatives) such as genistein (Fig. 2) and daidzein have shown promising anticancer effects including tumor growth inhibition and inhibition of metastasis formation by targeting multiple pathways (e.g., NF-κB, Akt, Wnt signaling, Notch signaling, androgen receptor signaling) [123]. Genistein downregulated the expression of oncogenic miR-21 in renal cancer cells (A498) followed by induction of p21 and p38 MAPK (mitogen-activated protein kinase) while cyclin E2 was suppressed by genistein [124]. In addition, numerous other oncogenic miRNAs are modulated by genistein. In renal cancer cells, downregulation of oncogenic miR-23b-3p was observed after treatment with genistein leading to expression of PTEN followed by suppression of PI3K (phosphatidylinositol-3-kinase), Akt and IL-32 (interleukin-32) [125]. Genistein reduced the levels of oncogenic miR-126b in renal cancer cells (786-O, A498) and, thus, inhibited Wnt signaling via upregulation of the miR-126b targets sFRP1 (frizzled-related protein 1), Dkk2 (dickkopf 2 homolog) and Smad4 (mothers against decapentaplegic 4) in these cancer cells [126].

### Table 2

| Compound       | Tumor suppressors (up-regulated) | Oncogenes (down-regulated) |
|----------------|---------------------------------|---------------------------|
| Curcumin       | let-7, miR-7, miR-9, miR-15, miR-16, miR-22, miR-29a, miR-145, miR-181b, miR-185, miR-192-5p, miR-200b/c, miR-203, miR-205-5p, miR-215, MEG3 | miR-17-5p, miR-20a, miR-21, miR-27a, miR-186*, miR-208 |
| CDF            | miR-34, miR-101, miR-146a, miR-200, miR-874 | miR-21, miR-210, miR-221 |
| EF24           | miR-33b                          | miR-21                    |
| Garcinol       | let-7, miR-128, miR-200b/c, miR-453, miR-720, miR-1280 | miR-21, miR-494, miR-495, miR-1977 |
| Garcinol + Gemcitabine | miR-453, miR-663, miR-638, miR-720 | miR-196a, miR-495, miR-605, miR-483-3p, miR-1914 |
Genistein performed analogously in prostate cancer cells (DU-145, PC-3) where suppression of miR-1260b and Wnt signaling was observed as well [127]. Oncogenic miR-27a was suppressed by genistein in various tumors including uveal melanoma (C918), pancreatic, and ovarian cancer (SKOV3) cells followed by induction of ZBTB10 (zinc-finger and BTB domain containing 10) and Sprouty2, the targets of miR-27a [128–130]. MiR-151, which targets various factors (e.g., N4BP1, CASZ1, SOX17, IL1RAPL1, ARHGDA), features another miRNA suppressed by genistein in prostate cancer cells (PC-3, DU-145) leading to inhibition of migration and invasion of prostate cancer cells [131]. Further to this, genistein blocked miR-221 and miR-222 expression in prostate cancer cells (PC-3) followed by overexpression of ARH1 (aplysia ras homolog 1) and cell growth, invasion and colony formation inhibition [132]. MiR-223 was likewise suppressed by genistein in pancreatic cancer cells and induction of Fbw7 (F-box and WD-40 domain protein 7) expression was observed leading to cancer cell growth inhibition and apoptosis induction [133]. The G2535 mixture of isoflavones (70.54% genistein, 26.34% daidzein, 0.31% glycitein) reduced oncogenic miR-221 levels in pancreas cancer cells and inhibited proliferation and migration of pancreas cancer cells by induced expression of p27, p57, PTEN, and PUMA [107]. In highly metastatic breast cancer cells (MDA-MB-435), genistein suppressed miR-155 expression accompanied by increased expression of various pro-apoptotic and antiproliferative miR-155 targets (FOXO3, PTEN, casein kinase, p27) [134].

In contrast to that, the tumor suppressor miRNAs miR-34a, miR-574-3p and miR-1296 were upregulated in prostate cancer cells (PC-3, DU-145) after treatment with genistein [135–137]. While genistein-mediated induction of miR-34a knocked down HOTAIR (HOX transcript antisense RNA), overexpression of miR-574-3p suppressed anti-apoptotic Bcl-xL and enhanced caspase-3 and caspase-9 activity. Further targets of miR-574-3p included RAC1, EGFR and EP300 (p300 histone acetyl transferase), while miR-1296 blocks MCM2 (minichromosome maintenance) expression which is a crucial factor for functional DNA replication. However, a differing miRNA modulation by the isoflavones genistein and daidzein was observed in three prostate cancer cell lines [138]. Genistein also upregulated miR-34a in pancreas cancer cells and, thus, induced apoptosis and tumor cell growth inhibition by inhibition of Notch-1 signaling [139]. In addition, let-7 and miR-200 were upregulated in pancreatic cancer after treatment with genistein followed by suppression of miR-200 targets such as ZEB1 (zinc finger E-box-binding homeobox 1), slug and vimentin which are correlated with EMT [140]. Genistein also induced miR-146a expression associated with suppression of pancreatic cancer cell invasion via downregulation of miR-146a-targets such as EGF, MTA-2, IRAK-1, and NF-kB [141]. More recently, genistein exhibited distinct cell growth inhibition of breast cancer cells (MCF-7) by up-regulation of miR-23b expression (56.69-fold compared with untreated cells) [142].

Licorice (Glycyrrhiza glabra) is a well known sweetening plant and has been applied in folk medicine against inflammations, and as an antioxidant, antibiotic, demulcent and expectorant drug [143]. Extracts of licorice contain significant amounts of the isoflavon glabridin (a phytoestrogen, Fig. 2), which has shown anti-inflammatory, neuro- and cardioprotective activities in addition to distinct anticancer properties (growth inhibition, antiangiogenic and anti-metastatic effects) [144–146]. Glabridin suppressed cancer stem cell-like features in hepatocellular carcinoma models (HepG2, Huh–7, MHC97H) by upregulation of miR-148a and suppression of the miR-148a target SMAD2 (small body size mothers against decapentaplegic) associated with inhibition of TGF(2 transforming growth factor)-B/SMAD2 signaling [147]. Similar results were obtained from breast cancer cells (MDA-MB-231, Hs-578T) treated with glabridin [148]. In addition, glabridin inhibited angiogenesis of breast tumors (MDA-MB-231, Hs-578T) by upregulation of miR-520a [149]. The expression of NF-kB was blocked by upregulated miR-520a in glabridin-treated breast cancer cells associated with inhibition of NF-kB/IL-6/STAT-3 signaling.

Glyceollins represent further natural isoflavonoids biosynthetically derived from soy isoflavones (e.g., daidzein) which exhibited interesting anticancer properties (Fig. 2) [150]. These anti-estrogenic and antioxidant compounds strongly suppressed miR-155, a tumor-suppressor in breast and ovarian cancer models (MCF-7 by 53.4%, BC-1 by 73.1%) and suppressed estrogen-mediated expression of the progesterone receptor [151]. In letrozole-resistant breast cancer cells glyceollin I suppressed ZEB1 (zinc-finger E-box-binding homeobox 1) expression leading to reversal of EMT in these resistant breast cancer cells [152]. In triple-negative breast cancer cells (MDA-MB-231, MDA-MB-468) a mixture of glyceollin I (68%), II (21%) and III (11%), isolated from soybean seeds incubated with Aspergillus sojae, reduced tumorigenesis by modulation of miRNAs. In particular, tumor suppressor miRNAs (miR181c, miR-181d) as well as EMT reversing miRNAs (miR-22, miR-29b, miR-29c, miR-30d, miR-34a, miR-195) were upregulated by glyceollins while oncogenic miRNAs increasing tumorigenesis (miR-21, miR-193a-5p), metastasis formation (miR-185, miR-224), migration and invasion (miR-486-5p) and mesenchymal cell maintenance (miR-542-5p) were downregulated by glyceollins [153]. The expression of NME1 (non-metastatic cells 1, target of miR-486-5p and miR-542-5p), was increased while vimentin (target of miR-30d) was reduced in glyceollins-treated breast cancer cells [153].

In addition to soy isoflavones, many natural flavonoid derivatives exhibited sound biological activities including antioxidant and anticancer properties. For instance, (-)-epigallocatechin-3-O-gallate (EGCG, Fig. 3), the main catechin flavanol of the tea plant (Camilla sinensis), revealed distinct anticancer activities by modulation of multiple targets [154]. The induction of apoptosis in hematoma cells after treatment with EGCG was associated with an upregulation of the tumor suppressor miR-16 and inhibition of anti-apoptotic Bcl-2 [155]. In addition, miR-210 was induced by EGCG in lung cancer cells leading to cell growth inhibition [156]. However, the same group disclosed only modest changes of 21 miRNAs after EGCG treatment leading to greater importance in lung cancer models in vivo [157]. For instance, down-regulation of miR-449c-5p (targets: ACSL1, elmod1, GAS1, ZFHX4), miR-374c-5p (targets: ART3, crn1, DN, EPNAS1, GAS1, ELOVL6, rbm24), and miR-450a-2-3p (targets: cd19, IGFBP5, ZFHX4) as well as upregulation of miR-144-3p (targets: AMM3CR3, Cnc2e, ZCCH2C) and miR-34b-5p (targets: Cnc2e, NRH1) was observed in vivo after EGCG treatment [157]. In melanoma cells, increased expression of let-7b via activation of 67LR (67-kDa laminin receptor) was observed after treatment with EGCG [158]. In addition, EGCG inhibited cell growth of osteosarcoma cells via upregulation of
miR-1 expression and induced apoptosis in osteosarcoma cells through induction of miR-126 expression [159,160]. Oncogenic miR-21 and AR (androgen receptor) signaling were suppressed in prostate cancer cells after EGCQ treatment while miR-330 was upregulated leading to reduced prostate tumor growth [161]. The microRNAs miR-30* (which targets NF-κB, peroxisome-proliferator activated receptor/PPAR signaling, insulin signaling, glycolysis, gluconeogenesis, oxidative phosphorylation, glutathione, glycolipids, and mitochondria), miR-453, miR-520-e, miR-608, and miR-629 were downregulated by EGCQ in hepatoma cells (HepG2) [162]. Tsang and coworkers showed that 61 miRNAs were modulated by EGCQ in hepatoma cells (HepG2) (e.g., upregulation of let-7c, miR-16, miR-18, miR-25, miR-92, and suppression of miR-129, miR-196b, miR-302, miR-342, miR-526) [163]. EGCQ-mediated suppression of miR-98-5p in NSCLC cells (A549) sensitized these tumor cells to cisplatin treatment [164]. The expression of further miRNAs was either reduced (oncogenic miR-92, miR-93, miR-106b) or increased (tumor suppressors miR-7-1, miR-34a, miR-99a) by a combination of EGCG with N-(4-hydroxyphenyl)retinamide in human neuroblastoma cells (SH-SYSY, SK-N-DZ) [165]. Protection from UVB irradiation was observed in EGCQ-treated dermal fibroblasts via modulation of various miRNAs [166]. Four miRNAs were upregulated (miR-1246, miR-548c-3p, miR-636, miR-933) and 14 miRNAs were downregulated (miR-1202, miR-1207-5p, miR-1225-5p, miR-1227, miR-1327, miR-133a, miR-134, miR-181d, miR-212, miR-362-3p, miR-455-5p, miR-494, miR-513a-5p, miR-660) in EGCQ-treated dermal fibroblasts [166]. By the way, EGCQ was shown to interact and to bind directly to certain miRNAs (miR-33a, miR-122) in liver cells and the miRNA binding ability of EGCQ was determined by 1H NMR spectroscopy [167].

The screening of a series of flavonoids revealed the outstanding activity of 3,6-dihydroxyflavone (3,6-DHF, Fig. 3) against breast cancer cells [168]. In addition, 3,6-DHF exhibited distinct chemopreventive effects in 1-methyl-1-nitrosourea treated breast cancer cells by upregulation of miR-34a and downregulation of miR-21 [169]. More recently, the same group disclosed an epigenetic mechanism for the modulation of miR-34a and miR-21 by 3,6-DHF in breast cancer cells [170]. Inhibition of the methyltransferase DNMT1 by 3,6-DHF (probably by binding to the cysteine pocket of the enzyme) blocked the hypermethylation of the miR-34a promoter which led to enhanced miR-34a expression [170]. Concerning miR-21, 3,6-DHF modulated histone modification and depressed H3K9-14ac in the miR-21 promoter region which led to miR-21 suppression and efficient blocking of the PI3K/Akt/mTOR signaling pathway [170].

Apigenin represents another flavone derivative found in fruits, herbs, and vegetables, which induced apoptosis both via the intrinsic and via the extrinsic pathway and suppressed PI3K/Akt and ERK1/2 signaling pathways in various cancer cells (Fig. 3) [171,172]. Apigenin was shown to inhibit tumor growth both in vitro and in vivo [173,174]. Decreased expression of miR-138 enhanced the telomerase activity in tumor cells, which is associated with malignant growth [175]. The transfection with hTERT short hairpin RNA (a shRNA, which inhibits hTERT, human telomerase reverse transcriptase) in combination with apigenin treatment increased the expression of miR-138 in neuroblastoma cells [175]. In addition, miR-138 led to enhanced anticancer activity of apigenin and caused increased apoptosis induction and inhibition of tumor cell growth and colony formation of neuroblastomas (SK-N-DZ, SK-N-BE2) by apigenin both in vitro and in vivo [175]. Obesity and diabetes are considered as significant risk factors for various cancer diseases [176]. In particular, miR-103 overexpression is associated with glucose intolerance and apigenin efficiently lowered miR-103 levels by impairing the maturation of this miRNA and by inhibition of ERK-mediated TRBP (trans-activating response RNA-binding protein) phosphorylation [177]. In this way, the miR-103 suppressing properties of apigenin may contribute to the prevention of obesity- and diabetes-induced cancer types.

The consumption of a diet rich in the flavonol quercetin (Fig. 3), which is found in apples, grapes and onions, was associated with the modulation of various miRNAs in lung cancer tissues that play a distinct role for tumorogenesis including miR-146a (upregulation) and miRNAs of the let-7 and miR-26 family (tumor suppressing let-7 and miR-26 miRNAs were significantly expressed upon quercetin consumption) [178]. Quercetin-mediated miR-146a expression which inhibited NF-κB signaling was associated with anti-inflammatory and cancer-preventive activity by protection of colonic myofibroblasts (CD-180c) from damage by ROS (reactive oxygen species) [179]. In addition, overexpression of let-7 by a combination of quercetin with catechins inhibited K-Ras signaling in pancreatic cancer cells as well as tumor growth inhibition [180]. In lung cancer cells (A549), quercetin induced miR-16 expression and decreased expression of the oncoprotein Claudin-2 in this way [181]. Unlike gemcitabine, quercetin also induced miR-142-3p expression in pancreatic cancer cells [182]. In hepatoma cells (HepG2), quercetin increased the levels of the tumor suppressor miR-34a associated with suppression of SIRT1 deacetylases in a p53-dependent way [183]. In contrast to that, oncogenic miR-294 expression was suppressed miR-378, miR-199a-3p and miR-181b in UVB-treated (Fig. 3) [186,187]. Baicalin induced expression of miR-23a and miR-155 in UVB-exposed cells associated with suppression of the inflammation factor MCP-1 (monocyte chemotactic protein 1), an effect that might contribute to the chemopreventive properties of baicalin as well [190].
The flavonolignan silybinin (Fig. 3) represents the active component of the fruits of the milk thistle (Silybum marianum) [191]. Recently, it was shown that silybinin suppressed miR-17, miR-21, miR-92a-2, miR-103-1, and miR-103-2, while tumor suppressor miR-663 (targeting TGF-β) was upregulated by resveratrol [195]. Oncogenic miR-21 was likewise downregulated by resveratrol in pancreatic cancer cells associated with enhanced apoptosis induction via suppression of the anti-apoptotic Bcl-2 protein [196]. Similar effects were observed from resveratrol-treated prostate cancer cells, where miR-21 suppression upregulated the miR-21 targets PDCD4 and maspin, and from gastric cancer cells treated with resveratrol [197,198]. The oncogenic miRNA clusters miR-17-92 and miR-106a/b were suppressed by resveratrol in prostate cancer cells leading to PTEN induction [199]. Resveratrol-mediated downregulation of miR-520h blocked metastasis formation of lung cancer models by inhibition of FOXD2 (forkhead box C2) [200]. The combination of resveratrol and quercetin reduced miR-27a levels leading to ZBTB10 expression and apoptosis induction in HT-29 colon cancer cells [184]. Resveratrol inhibited proliferation of MCF-7 breast cancer cells by upregulation of miR-663 and miR-774 leading to EFA12 (elongation factor 1A2) inhibition [201]. In addition, decreased cell invasion by induction of miR-141 and reversal of EMT via miR-200c upregulation (leading to ZEB1 suppression and E-cadherin upregulation) was observed after resveratrol treatment [202]. Synergy effects were observed in lung cancer cells from the combination of resveratrol with miR-200c [203]. Further to this, resveratrol-mediated up-regulation of the tumor suppressor miR-34a was associated with increased cell growth inhibition and apoptosis induction in colon cancer cells [204]. In addition, the tumor suppressor miR-34c was induced by resveratrol in colon cancer cells (HT-29, HCT-116) leading to increased apoptosis and suppression of the miR-34c target KITLG (also known as stem cell factor SCF) in vitro and in vivo [205]. The tumor suppressor miR-622 targets K-Ras and was found to be upregulated by resveratrol in transformed bronchial epithelial cells (16HBE-T) leading to cell cycle arrest and suppressed colony formation and tumorigenicity [206]. In hormone-sensitive breast tumors resveratrol inhibited DNA-methyltransferase DNMT3b by upregulation of miR-129, miR-204, and miR-489 [207]. A general miRNA expression study in A549 lung cancer cells revealed that resveratrol suppressed miR-29a-2 and induced miR-299-5p, miR-194*, miR-338-3p, miR-758, and miR-582-3p which are likely involved in the regulation of proliferation, apoptosis, cell cycle and differentiation processes of lung cancer cells [208]. More recently, a similar study was carried out with triple-negative MDA-MB-231 breast cancer cells and resveratrol strongly upregulated miR-122-5p (37-fold) and significantly downregulated miR-542-3p (11-fold) and miR-200c-3p (8-fold) playing a key role for the anticancer effects of resveratrol in these cancer cells [209]. Like EGCG, resveratrol was able bind directly to certain miRNAs (miR-33a, miR-122) in liver cells and the miRNA binding ability of resveratrol was determined by 1H NMR spectroscopy [167].

Piceatannol is a close stilbene analog of resveratrol (Fig. 4) and occurs in many fruits, in particular, in grapes and red wine which was associated with the so-called “French paradox” together with resveratrol. Indeed, piceatannol exhibited distinct anticancer properties via multiple pathways, and it revealed higher inhibition of COX-1/2 and CSN-associated kinase than resveratrol [210]. In leukemia cells (U937), Akt/Foxp3-mediated miR-183 expression was suppressed by piceatannol leading to inhibition of Sp1-induced metalloprotease ADAM17 expression and suppression of TNFα-induced NF-κB [211]. The expression of the tumor suppressor miR-129 was up-regulated by piceatannol in colon cancer cells

### Table 3
Regulation of microRNAs by flavonoids.

| Compound       | Tumor suppressors (up-regulated)       | Oncogenes (down-regulated)                  |
|----------------|----------------------------------------|--------------------------------------------|
| Genistein      | let-7, miR-23b, miR-34a, miR-146a, miR-200, miR-574-3p, miR-1296 | miR-21, miR-23b, miR-27a, miR-151, miR-155, miR-221, miR-222, miR-223, miR-1206b |
| Galbrinid      | miR-148a, miR-520a                      | miR-21, miR-185, miR-193a-5p, miR-224, miR-486-5p, miR-542-5p |
| Gycollins      | miR-22, miR-29b, miR-29c, miR-30d, miR-34a, miR-181c, miR-181d, miR-195 | miR-21, miR-30*, miR-92, miR-93, miR-98-5p, miR-106b, miR-374c-5p, miR-449c-5p, miR-450a-2-3p, miR-453, miR-520-e, miR-608, miR-629 |
| EGCG           | let-7b, let-7c, miR-1, miR-7-1, miR-16, miR-18, miR-25, miR-34a, miR-34b, miR-92, miR-99a, miR-126, miR-144-3p, miR-210, miR-330 | miR-103 (glucose intolerance) |
| 3,4-DHF        | miR-34a                                 | miR-27a, miR-125b-3p                         |
| Apigenin       | miR-183                                 | miR-181b, miR-199a-3p, miR-294, miR-378, miR-21 |
| Quercerin      | let-7, miR-16, miR-25, miR-34a, miR-146a, miR-142-3p | miR-21 |
| Baicalin, Baicalein | miR-23a, miR-124 (anti-inflammatory) | miR-21 |

**Fig. 4.** Chemical structures of stilbenes, anthraquinones, xanthone and anthrancne derivatives.
(HCT-116, HT-29) and increased apoptosis was observed in piceatannol-treated cells via suppression of Bcl-2 (target of miR-129) [212]. Bone metastasis are difficult to tackle and cause painful and life-threatening bone damages, however, both resveratrol and piceatannol were shown to block osteoclastogenesis by down-regulation of miR-183 via HO-1 (heme oxygenase-1) induction and, thus, feature suitable tools for the management and prevention of bone metastasis [213]. A list of miRNAs regulated by natural stilbenes is given in Table 4.

Table 4

| Compound | Tumor suppressors (up-regulated) | Oncogenes (down-regulated) |
|----------|---------------------------------|-----------------------------|
| Resveratrol | miR-34a/c, miR-122-5p, miR-141, miR-194*, miR-200k, miR-299-5p, miR-338-3p, miR-582-3p, miR-622, miR-663, miR-758, miR-774 | miR-17, miR-21, miR-25, miR-27a, miR-92a-2, miR-103-1, miR-103-2, miR-183, miR-200-3p, miR-520h, miR-542-3p, miR-17-52 cluster, miR-106ab cluster, miR-183 |
| Piceatannol | miR-129 | miR-17, miR-21, miR-25, miR-27a, miR-92a-2, miR-103-1, miR-103-2, miR-183, miR-200-3p, miR-520h, miR-542-3p, miR-17-52 cluster, miR-106ab cluster |

3.1.5. Anthraquinones, xanthone and anthracene derivatives

Doxorubicin (Adriamycin, Dox) is a natural anthracycline anti-cancer drug (inhibitor of topoisomerase II, isolated from Streptomyces bacteria) widely applied for the treatment of various advanced cancer diseases including metastatic breast cancer (Fig. 4) [214]. Resistance factors concerning doxorubicin treatment include the expression of ABC-transporters (increased drug efflux), enhanced drug metabolism, reduced topoisomerase II levels, altered p53 function, and apoptosis inhibition [214]. Restored miR-128 expression in breast cancer stem-like cells (BCSCs) enhanced the activity of doxorubicin and increased apoptosis and DNA damage in these drug resistant cells [215]. In addition, miR-218 showed an increased apoptosis induction [221]. Low levels of miR-218 were associated with upregulated anti-apoptotic Mcl1 (DNMT1) were suppressed by doxorubicin [231]. The application of miR-221-conjugated miR-221 molecular beacon suppressed miR-221 expression efficiently while increased anticancer efficacy was observed in treated glioblastoma cells [232]. In diffuse large B-cell lymphoma (DLBCL) cells, the expression of miR-199a and miR-497 distinctly sensitized these lymphoma cells to doxorubicin treatment. In addition, better overall survival was observed in DLBCL patients with high miR-199a and miR-497 expression [233]. A list of miRNAs involved in doxorubicin-resistance is given in Table 5.

Emodin (1,3,8-trihydroxy-6-methylanthraquinone) features another natural anthraquinone derivative which was isolated from the roots of the Turkish rhubarb Rheum palmatum, a plant applied in TCM for the treatment of several diseases (Fig. 4) [234]. Emodin exhibited distinct anticancer activities via inhibition of tyrosine kinases [235]. Oncogenic miRNAs miR-221 and miR-222 were suppressed by emodin in leukemia cells (K562) leading to the induction of erythroid differentiation by upregulation of ALAS2 (aminolevulinate synthase) and of the tyrosine kinase c-KIT [235]. The growth inhibitory effects of emodin in lung cancer cells (A549) was associated with upregulation of miR-211 and miR-429 expression and suppression of their targets SATB2 (special AT-rich sequence-binding protein 2) and CRKL (Crk-like protein) [236]. The combination of emodin with curcumin revealed synergistic effects on drug-resistant lung cancer cells.
effects concerning the inhibition of breast cancer cell proliferation and invasion via upregulation of miR-34a and suppression of the miR-34 targets Bcl-2 and Bmi-1 [237]. In addition, emodin was able to suppress Wnt4/Dvl-1/β-catenin signaling by induction of miR-126 expression [238]. Angiogenesis of pancreatic cancer was blocked by emodin via upregulation of miR-20b and down-regulation of miR-155 and miR-210 leading to reduced TGF-β levels and inhibition of the TGF-β/Smad pathway [239].

Mangiferin represents an important bioactive component of the Mango plant (Mangifera indica) [240]. Chemically, mangiferin features a C-glucosidic xanthone (2-C-β-D-glucopyranosyl-1,3,6,7-tetrahydroxyxanthone, Fig. 4) with potent antioxidant, anti-inflammatory, anti-diabetic, and anticancer activities (e.g., with activity against breast, colon, lung and prostate cancer as well as anti-angiogenic activity) [240]. Inhibition of NF-κB and PI3K/Akt was observed for mangiferin [240]. In prostate cancer cells (PC-3), mangiferin stopped cell growth and induced apoptosis via upregulated miR-182 expression associated with suppressed Bcl-2 expression [241]. In addition, apoptosis induction and levels of distinct anticancer and anti-inflammatory activities. These properties correlated with the inhibition of NF-κB and further inflammatory factors in various cancer cells [248]. A pomegranate extract with significant contents of the ellagitannins punicalagin A, punicalagin B (Fig. 5), and of the anthocyanins delphinidin-3-glucoside and cyanidin-3-glucoside was tested against breast cancer cells (BT-474, MDA-MB-231) [248]. Indeed, the pomegranate extract reduced miR-27a levels in these breast cancer cells associated with increased ZBTB10 (Sp-repressor) expression and reduced levels of Sp, VEGF, VEGFR (vascular endothelial growth factor receptor) and survivin [248]. In addition, pomegranate extract suppressed miR-155 leading to upregulation of inositol phosphatase SHIP-1 and inhibition of PI3K/Akt signaling [248]. Pomegranate extract also suppressed DNA repair and led to double-strand breaks (DSBs) accompanied by increased apoptosis in MCF-7 breast cancer cells via upregulation of miR-24 and miR-183 [249]. Pomegranate extracts likewise induced miR-34a expression depending on activated p53 leading to suppression of c-Myc and CD44 and increased apoptosis induction in EJ bladder cancer cells [250].

1’-Acetoxychavicol acetate (Fig. 5), a phenolic compound isolated from Alpinia conchigera (wild ginger), modulated the expression of miRNAs in cervix carcinoma cells (Ca Ski, HeLa) [251]. More precisely, the tumor suppressor miRNAs miR-138, miR-210 and miR-744 were upregulated by 1’-acetoxychavicol acetate in combination with cisplatin [251]. In addition, oncogenic miR-23a was suppressed in head-and-neck squamous cells (HN4) associated with PTEN upregulation and increased apoptosis induction after treatment with 1’-acetoxychavicol acetate [252].

### Table 5

MicroRNAs involved in doxorubicin-resistance of cancer cells.

| Tumor suppressors (down-regulated) | Oncogenes (up-regulated) |
|-----------------------------------|--------------------------|
| let-7, miR-27b, miR-34a, miR-34b, miR-101, miR-125b, miR-127, miR-128, miR-139b, miR-199a, miR-200c, miR-205, miR-218, miR-450b-3p, miR-451, miR-497, miR-522, miR-542-3p | miR-10b, miR-21, miR-28, miR-106a, miR-181a, miR-202, miR-206, miR-221, miR-548c-3p |

### Table 6

Regulation of microRNAs by emodin, mangiferin, and mithramycin A.

| Compound         | Tumor suppressors (up-regulated) | Oncogenes (down-regulated) |
|------------------|----------------------------------|-----------------------------|
| Emodin           | miR-20b, miR-34a, miR-126, miR-211, miR-429 | miR-155, miR-210, miR-221, miR-222 |
| Mangiferin       | miR-15b, miR-182                 | —                           |
| Mithramycin A    | miR-210                          | —                           |

Fig. 5. Miscellaneous phenolic derivatives.
The biphenol magnolol, [4-allyl-2-(5-allyl-2-hydroxyphenyl) phenol], was isolated from Magnolia obovata which has been applied in the Japanese folk medicine for the treatment of cough and gastrointestinal diseases (Fig. 5) [253]. Magnolol exhibited growth inhibitory and anti-metastatic activity against various cancer types and suppressed Wnt signaling in colon cancer cells [253]. In breast cancer cells (MCF-7), the expression of the tumor suppressor miR-200c was increased after treatment with magnolol leading to ZEB1 inhibition and E-cadherin upregulation [254]. Honokiol, [2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol], features a close analog of magnolol which was isolated from various Magnolia species (M. officinalis, M. obovata, M. grandiflora) of Southeast and East Asia (Fig. 5) [255]. The biphenol honokiol revealed distinct anti-oxidative, anti-inflammatory and anticancer activities by targeting multiple factors including signaling pathways of NF-κB, EGFR, STAT-3 and mTOR (mammalian target of rapamycin) [256]. In breast tumors, honokiol inhibited tumor growth via increased expression of miR-34a and STAT-3 inhibition associated with suppression of the Wnt1-MTA-β-catenin signaling pathway [257]. Honokiol also inhibited the growth of bladder tumors by increased expression of the tumor suppressor miR-143 leading to suppression of EZH2, MMP-9, CD44, and Sox2 [258].

Caffeic acid (3,4-dihydroxyxinnamic acid) and its phenethyl ester CAPE belong to the active constituents of the propolis extract, a honey bee hive extract, and also occur in various plants (Fig. 5) [259]. Caffeic acid and CAPE [259]. A significant suppression of angiogenesis was observed after treatment with caffeic acid and CAPE [259]. In hepatocarcinoma cells (HepG2, MHCC97H), caffeic acid increased miR-124 levels via DNA-demethylation associated with suppression of NF-κB/p65, STAT-3, and IL-6 (interleukin-6) [260]. In addition, caffeic acid suppressed cancer stem cell-like features by induction of miR-148a leading to inhibition of the TGF-β/SMAD2 signaling pathway and blocking of SMAD2 expression by miR-148a that binds to the SMAD2-3′UTR [263]. CAPE downregulated pro-inflammatory miRNAs (miR-9, miR-125b, miR-146a, and miR-155) in neuronal cells exposed to Alzheimer’s disease derived extracellular fluid via inhibition of NF-κB which might play a role for the anticancer properties of CAPE as well [264]. Rosmarinic acid (isolated from rosemary, Rosmarinus officinalis) features another caffeic derivative with distinct antioxidant, anti-inflammatory and anticancer effects (Fig. 5) [265]. In gastric cancer cells (MKN45), rosmarinic acid revealed an anti-Warburg effect, i.e., it suppressed glycolytic biosynthesis of ATP which is a common feature of many cancer types [266]. Down-regulation of the microRNAs miR-155, miR-146a and miR-223 was observed after treatment with rosmarinic acid as well as suppression of STAT-3, IL-6 and HIF-1α (hypoxia inducible factor) [266]. Table 7 provides a list of miRNAs modulated by various phenolic natural compounds.

### Table 7

| Compound | Tumor suppressors (up-regulated) | Oncogenes (down-regulated) |
|----------|----------------------------------|---------------------------|
| BJA32515 | let-7a, miR-29a                   | miR-197, miR-373           |
| Pomegranate extract & 1′-Acetoxychavicol acetate | mir-24, mir-183 | mir-27a, miR-155, miR-23a |
| Magnolol | mir-138, mir-210, mir-744         |                           |
| Honokiol | mir-200c, mir-34a, mir-143        | miR-9, miR-125b, miR-146a, miR-155, miR-223 |
| Caffeic acid, CAPE, Rosmarinic acid | mir-124, mir-148a |                           |

The topoisomerase II inhibitor and approved anticancer agent etoposide is derived from the natural product podophyllotoxin and is applied in advanced stages of breast cancer, lung cancer, leukemia and lymphoma diseases (Fig. 5) [267,268]. Dean and coworkers investigated the influence of miRNAs on etoposide sensitivity and etoposide resistance of breast cancer cells (sensitive MCF-7, resistant MCF-7/VP) [269]. A significant upregulation of miR-382, miR-23b and miR-885-5p (>2-fold) and suppression of miR-218, miR-758 and miR-548d-5p (>2-fold) was observed from etoposideresistant MCF-7/VP cells when compared with sensitive MCF-7 cells [269]. MiR-218 was particularly down-regulated (7.79-fold) in the resistant MCF-7/VP cells. The authors assumed a link between the modulation of these miRNAs with the significant upregulation of ABC transporters such as ABC1C1 and ABCG2 in the resistant MCF-7/VP cells, which remove etoposide from the cancer cells again [269]. Recently, increased levels of miR-124 upregulated the CDK (cyclin-dependent kinase) inhibitor p27 leading to G1 arrest and sensitized breast and ovarian cancer tumors to etoposide treatment [270]. In hepatoma carcinoma, increased miR-23a expression enhanced the activity of etoposide by suppression of topoisomerase 1, the target of miR-23a, and miR-23a expression depended on functional p53 [271]. HepG2 hepatoma cells were turned into etoposide-resistant cells by upregulation of miR-210 (induced by hypoxia) while upregulation of miR-196b sensitized hepatoma cells to etoposide via suppression of IGF2BP1 (insulin-like growth factor 2 RNA binding protein 1) [272]. Expression of miR-1915-3p in lung cancer cells inhibited etoposide-induced apoptosis by suppression of DRG2 (developmentally regulated GTP-binding protein 2) and PBX2 (pre-B cell leukemia homeobox 2) [273]. In contrast to that, expression of miR-1469 enhanced apoptosis induction by etoposide in lung cancer cells via suppression of STAT5A [274]. The induction of miR-153 reduced the anticancer activity of etoposide in HCC cells via upregulation of survivin and Bcl-2, and inhibition of p21, PTEN and FOXO1 [275]. In addition, osteosarcoma cells responded to etoposide treatment by activation of the tumor suppressor miR-34a in a p53-dependent way [276]. A list of miRNAs involved in etoposide-resistance and —sensitivity is provided in Table 8.

### Table 8

| miRNAs involved in etoposide resistance and sensitivity. |
|---------------------------------------------------------|
| Etoposide-resistance                                      |
| miR-23b, miR-153, miR-210, miR-382, miR-885-5p, miR-1915-3p |
| Etoposide-sensitivity                                   |
| miR-23a, miR-34a, miR-124, miR-196b, miR-218, miR-548d-5p, miR-758, miR-1469 |
cells, while miR-27a was suppressed by AKBA and curcumin. The modulation of these miRNAs was also observed from colon cancer xenografts (HCT-116) upon treatment with AKBA and curcumin associated with tumor growth inhibition when compared with untreated tumors [282].

The bioactive triterpene betulinic acid (Fig. 6) occurs in birch and plane trees and is easily isolated in significant amounts from the fallen bark of plane trees (Platanus acerifolia) [283]. Betulinic acid has revealed topoisomerase I inhibition and exhibited distinct and selective anticancer activity in mouse xenografts (ovarian cancer, melanoma) while it was non-toxic to the organism at doses up to 500 mg/kg [284,285]. In colon cancer cells (RKO, SW480), betulinic acid exhibited growth inhibitory and pro-apoptotic effects via suppression of miR-27a and induction of the Sp repressor ZBTB10 (miR-27a target) [286]. Similar effects were observed from estrogen-negative breast cancer cells (MDA-MB-231) after treatment with betulinic acid [287]. Interestingly, the usually oncogenic miR-21 was upregulated by betulinic acid in hepatoma cells in a p53-dependent way and contributed to the pro-apoptotic properties of betulinic acid by suppression of Sod2 [288]. In this special case, miR-21 revealed clear tumor suppressor properties upon activation by betulinic acid. In addition, betulinic acid suppressed miR-33 and NF-κB in lipopolysaccharide-treated macrophages and promoted the expression of the ABC-transporter ABCA1 that is responsible for the transport of cholesterol and phospholipids [289].

Ursolic acid features another natural triterpene found in herbal drug plants such as Radix actinidiae and Oldenlandia diffusa and revealed significant anti-inflammatory and anti-cancer activities (Fig. 6) [290,291]. In U251 glioma cells, ursolic acid inhibited tumor cell growth via reduced miR-33 and NF-κB in lipopolysaccharide-treated macrophages and promoted the expression of the ABC-transporter ABCA1 that is responsible for the transport of cholesterol and phospholipids [289].

Aside glabridin isoflavans, licorice extracts also contain significant amounts of the triterpene glycyrrhetinic acid (enoxolone, up to

Fig. 6. Chemical structures of triterpene derivatives.
problem in the clinic and miRNAs are involved in sensitivity or resistance to paclitaxel. Forty human cancer cell lines were investigated for miRNAs involved in in vitro sensitivity to paclitaxel and two miRNAs, miR-30a-5p and miR-367, were identified to play a crucial role [306]. While expression of miR-367 increased paclitaxel activity, expression of miR-30a-5p reduced paclitaxel efficacy in cancer cells [306]. In ovarian cancer cells (A2780), paclitaxel sensitivity was associated with miR-149 downregulation and enhanced MyD88 expression [307]. In addition, increased expression of miR-320a, miR-22 and miR-129-5p as well as reduced expression of miR-9, miR-155 and miR-640 were observed in ovarian cancer cells resistant to paclitaxel (ST30 cells) [308]. The miR-9 target RAB34 (a GTPase) might play a role in the observed paclitaxel-resistance [308]. MiR-433 features another oncogenic miRNA that is upregulated in paclitaxel-resistant ovarian cancer cells (A2780) leading to suppression of CDK6 and to cellular senescence [309]. In addition, expression of miR-130b and of miR-197 contributed to paclitaxel-resistance in ovarian cancer cells [310,311]. Paclitaxel-resistant epithelial ovarian cancer revealed high levels of miR-1307, which was associated with drug resistance [312]. Mimics of miR-200c and miR-141 sensitized drug-resistant ovarian carcinoma cells (MES-OV) to paclitaxel treatment via reversal of EMT (induction of E-cadherin, suppression of vimentin) [313]. Further to this, expression of miR-873 downregulated the drug efflux transporter ABCB1 and increased the anticancer activity of paclitaxel in ovarian cancer cells [314]. Distinctly increased expression of miR-622 and miR-663 featured bad prognosis factors for patients suffering from taxol-resistant ovarian cancer, while expression of miR-647 indicated good prognosis for taxol-sensitive ovarian cancer patients [315].

The expression of miR-125a

24% in licorice root extracts) which showed strong apoptosis induction in cancer cells (Fig. 6) [293]. Enoxolone blocked tumor cell invasion via upregulated miR-200c expression in breast cancer cells accompanied by ZEB1 suppression and E-cadherin upregulation [254]. The semi-synthetic glycyrrhetinic acid derivative CDODA-Me (methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate, Fig. 6) inhibited colon cancer growth (RKO, SW480) in vitro and in vivo via reduction of miR-27a levels associated with increased expression of the Sp repressor ZBTB10 and upregulation of Myt-1 which causes G2/M arrest by cdc2 phosphorylation [294]. Interestingly, the gap junction blocker 18α-glycyrrhetinic acid (18-AGA) was able to inhibit the intercellular transfer of miRNAs efficiently [295].

Cucurbitacins represent further triterpenes with amazing biological properties. Cucurbitacin I (Fig. 6), for instance, inhibited JAK/STAT-3 signaling accompanied with strong anticancer activity in mice [296]. CD4+ T cells (cutaneous T-cell lymphoma, Sézary syndrome) treated with cucurbitacin I showed reduced IL-21-mediated oncogenic miR-21 expression and, thus, IL-21 promoted miR-21 expression strongly depended on STAT-3 activation [297]. Apoptosis induction in CD4+ T cells by cucurbitacin I was in parts mediated by miR-21 suppression. Similarly, the IL-21-induced and STAT-3-dependent expression of miR-155 was downregulated by mediated by miR-21 suppression. In addition, STAT-3 targeting/suppressing miRNAs such as miR-337-3p revealed synergistic effects in combination with cucurbitacin I in NCI-H1155 lung cancer cells and the IC50 values of cucurbitacin I were improved in these cells when cotreated with miR-337-3p (IC50 = 0.37 μM in miR-337-3p co-treated cells, IC50 = 1.14 μM for cucurbitacin I alone) [299].

Ginsenosides are triterpene saponins with a terpenoid steroidal nucleus connected to a sugar fragment and were isolated from the ginseng plant that is widely applied as a herbal drug both in East Asia and in the West [300]. In glioma cells (U251), ginsenoside Rh2 (Fig. 6) induced miR-128 expression and suppressed miR-21 associated with tumor cell growth inhibition and apoptosis induction in these tumor cells [301]. The Rh2-mediated modulation of microRNA expression of A549 non-small cell lung cancer cells was determined and miR-148a was distinctly upregulated (9.59-fold) by Rh2 in these lung cancer cells [302]. MiR-148a expression revealed significant antitumor effects in various cancer models and, thus, likely contributes to the anticancer effects of Rh2 as well. In addition, oncogenic miR-21, miR-23b, miR-27b, miR-100, miR-221 (4.9-fold) and miR-424 (12.4-fold) were downregulated by Rh2 in A549 lung cancer cells [302]. Ginsenoside Rg3 features another triterpene saponin derivative of red ginseng that efficiently blocked angiogenesis via upregulation of miR-520h leading to suppression of the ephrin receptors EphB2 and EphB3 (Fig. 6) [303]. A list of microRNAs regulated by triterpenes is presented in Table 9.

3.2.2. Diterpenes, sesquiterpenes and monoterpene

Paclitaxel (taxol) is a clinically approved natural diterpene anticancer drug initially isolated from the Pacific yew (Taxus brevifolia) that induces cell death via microtubule stabilization (Fig. 7) [304,305]. The formation of paclitaxel resistance is a serious
sensitized cervical cancer to paclitaxel via suppression of STAT3, while miR-375 expression reduced paclitaxel sensitivity by induction of EMT processes [316, 317]. MiR-490-3p features another oncorm in ovarian cancer cells that mediates paclitaxel resistance via upregulation of Pgp and GST-π [318]. Induction of miR-134 in endometrial cancer cells (ECS) promoted paclitaxel activity by inhibition of POGLU1 (protein O-glucosyltransferase 1) and Notch signaling [319]. Reduced levels of miR-218 were found in taxol-resistant breast cancer cells, and re-expression of miR-218 broke the resistance to taxol via inhibition of survivin [222]. Upregulation of the RNA-processing enzyme Dicer induced the expression of miR-494 and increased the activity of paclitaxel in breast cancer via suppression of AXL kinase [320]. In contrast to that, expression of miR-520b promoted paclitaxel-resistance in breast cancer cells associated with induction of DAPK2 (death-associated protein kinase 2) expression [321]. Breast cancer cells expressing miR-621 inhibited FBXO11 expression and activated p53 leading to enhanced sensitivity to paclitaxel treatment [322]. Patients suffering from luminal A subtype breast cancer resistant to neoadjuvant chemotherapy (NAC, paclitaxel plus epirubicin) exhibited distinctly stronger expression of miR-19a and miR-205 than drug-sensitive patients [323]. In addition, breast cancer patients who received NAC exhibited increased expression of miR-34a and miR-122, which may contribute to the anticancer activity of paclitaxel and epirubicin [324]. In paclitaxel-resistant lung cancer cells, miR-16 and miR-17 were downregulated leading to induction of anti-apoptotic Bcl-2, and expression of miR-16 and miR-17 enhanced apoptosis induction by paclitaxel via suppression of Bcl-2 as well as autophagy inhibition by Beclin-1 downregulation [325]. In addition, miR-17-5p was downregulated in paclitaxel-resistant lung cancer cells accompanied by Beclin-1 upregulation [326]. A pH-dependent liposomal formulation of a combination of antagonir-10b and paclitaxel released antagonir-10b and paclitaxel at lower cancer cells accompanied by Beclin-1 upregulation (expression of caspase-3/7) and enhanced distinctly the anti-proliferative effects of paclitaxel in NSCLC cells (H1993) [337]. A list of miRNAs involved in paclitaxel-resistance and —sensitivity is provided in Table 10.

| miRNAs involved in paclitaxel resistance and sensitivity. |
|----------------------------------------------------------|
| **Paclitaxel-resistance**                                  |
| miR-19a, miR-21, miR-22, miR-30a-5p, miR-129-5p, miR-130b, miR-149, miR-153, miR-133a/b, miR-197, miR-205, miR-361-3p, miR-375, miR-433, miR-490, miR-520h, miR-622, miR-663, miR-1307 |
| **Paclitaxel-sensitivity**                                 |
| let-7b, miR-9, miR-10b, miR-16, miR-17, miR-17-5p, miR-34a, miR-122, miR-125a, miR-130a, miR-134, miR-141, miR-155, miR-200c, miR-218, miR-367, miR-494, miR-497, miR-647, miR-873, miR-877, miR-1204 |

Triptolide features an anticancer active diterpene trioxipide lactone of the Chinese plant *Tripterygium wilfordii* (thunder god vine, applied in TCM) and suppressed the heat shock protein Hsp70 in cancer cells associated with cancer cell growth inhibition [Fig. 7] [182]. Unlike the approved anti-pancreatic cancer drug gemcitabine, triptolide also induced miR-142-3p expression (a miRNA repressor of Hsp70) in pancreatic cancer cells, while mnnelide, the water-soluble triptolide prodruge, increased miR-142-3p expression in vivo in a pancreatic cancer xenograft model [182]. Further to this, triptolide augmented the MDM2-suppressing effects of miR-339-5p both in MCF-7 breast cancer and in HCT-116 colon cancer cells lines after induction of the p53 inhibitor MDM2 by the approved anticancer drug 5-FU [340].

Aside rosmarin acid, rosemary (*Rosmarinus officinalis L.*) extracts also contain bioactive diterpenes such as carnosol and carnosic acid [Fig. 7] [341]. Both carnosol and carnosic acid showed antitumor activity against pancreatic and colon cancer both in vitro and in vivo by suppression of miR-15b and induction of glycosyltransferase GCNT3 [342]. In addition, carnosic acid in combination with 1,25-dihydroxyvitamin D3 reduced miR-181a levels in leukemia cells (HL-60, U937) leading to cell cycle arrest and cell differentiation [343].

Sesquiterpenes have shown potent anticancer activities, for instance, the fungal compound class of illudins exhibited strong tumor growth inhibitory activity via unique DNA binding properties [344]. The sesquiterpene lactone parthenolide (Fig. 7) isolated from feverfew (*Tanacetum parthenium*) has also shown distinct anticancer activity in various cancer cell lines and parthenolide showed NF-kB inhibition and DNA hypomethylation via DMT1 suppression [345]. Thus, miRNA modulation by parthenolide was assumed and in acute myelogenous leukemia cells (MOLM-13), parthenolide indeed increased the expression of the known tumor suppressors miR-15a and miR-16 [346].
The medicinal fungus *Antrodia camphorata* contains the sesquiterpene lactone antrocin ([Fig. 7](#)) that has revealed strong anticancer activity in triple-negative breast cancer cells (MDA-MB-231) [347]. In addition, antrocin revealed growth inhibition and apoptosis induction in lung cancer cells (H441, gefitinib-resistant H1975) via increased let-7c expression associated with STAT3 inhibition [348]. Another Southeast Asian ginger sesquiterpene, zerumbone ([Fig. 7](#)), induced apoptosis in Panc-1 pancreatic cancer cells via increased expression of miR-34a accompanied by p53 and p21 activation [349].

Sesquiterpenes such as menthol have shown antimutator activity against various cancer cells, and monoterpene conjugates even overcome cisplatin-resistance [350–352]. Thymoquinone (TQ, [Fig. 7](#)) represents the active monoterpene component of the oil of black seeds (*Nigella sativa*), a frequently applied plant (*kalonji*) in traditional Indian medicine (Ayurveda, Unani), and exhibited significant antineoplastic effects [353]. Among others, poly-l-like nases (PIk) were identified as tumor targets for thymoquinone [354]. Recently, a PEGylated thymoquinone nanoparticle (PEG4000-TQ-Np, PEG = polyethylene glycol) with improved aqueous solubility and tumor selectivity was prepared and investigated for its anticancer properties in breast cancer cells [355]. This nanoparticle exhibited increased breast tumor cell killing and anti-migratory activity by upregulation of miR-34a and downregulation of its target Rac1 (a Rac GTPase) leading to actin depolymerisation [355].

Paeoniflorin represents a major monoterpene glucoside of the medicinal plant *Paeonia lactiflora* Pall. and blocked tumor cell invasion and metastasis ([Fig. 7](#)) [356]. Paeoniflorin also inhibited glioma cell growth (U87) and induced apoptosis in glioma cells via upregulation of miR-16 and suppressed MMP9 expression [357]. In addition, paeoniflorin showed protective effects on doxorubicin-treated cardiomyocytes via suppressed miR-1 expression and inhibition of doxorubicin-induced apoptosis in cardiomyocytes [358]. A list of microRNAs regulated by di-, sesqui- and monoterpene is presented in Table 11.

### 3.2.3. Terpenoidal vitamins A, D, and E

Retinoic acid (RA, vitamin A, [Fig. 8](#)) is an essential natural diterpene for the regulation of cell growth and differentiation through binding to retinoic acid receptors (RARs) and revealed anticancer effects in various cancer models including breast, prostate, lung, liver, and pancreatic cancer [359]. In acute promyelocytic leukemia cells, retinoic acid induced the expression of several miRNAs such as let-7a-3, let-7c, miR-15a, miR-16-1, miR-107, miR-186, miR-215, miR-223, and miR-342, while five miRNAs (miR-17, miR-25, miR-93, miR-193, miR-181b) were suppressed after treatment with retinoic acid [360,361]. Though the inhibition of breast cancer cell growth by retinoic acid was counteracted by RA-induced expression of miR-21, RA-induced expression of miR-21 also inhibited the motility of estrogen-receptor (ER)-positive breast cancer cells (MCF-7) and suggested a beneficial effect concerning the anti-metastatic properties of retinoic acid via suppression of maspin [362]. In neuroblastoma cells (SH-SY5Y), retinoic acid induced differentiation via upregulation of miR-10a and miR-10b [363]. The SR-family splicing factor SFRS1 was identified as an important target of miR-10a and miR-10b upon treatment with retinoic acid. In addition, miR-10a and miR-10b mediated the anti-migratory and anti-metastatic activity of retinoic acid in these neuroblastoma cells [363]. In addition, retinoic acid induced neuroblastoma differentiation by upregulation of miR-9 and miR-103 associated with suppression of the expression of the differentiation inhibitor ID2 (inhibitor of DNA binding-2) [364]. In breast cancer, levels both of RARβ and of the tumor suppressor miR-10a were reduced and a positive correlation between miR-10a and RARβ was assumed [365]. Indeed, retinoic acid was able to upregulate miR-10a expression (2-fold) in breast cancer cells either alone (in SK-BR-3 cells) or in combination with thyroid hormone receptor THRα-binding α-thyroxine (in T47D cells) [365]. Retinoic acid also downregulated c-Myc and miR-130a in cancer cells leading to increased HOXA5 expression and cell death [366]. The differentiation of embryonic stem cells (ESCs) was induced by retinoic acid via suppression of miR-200b and miR-200c and of pluripotent genes such as Oct4 and Nanog [367]. Hence, in this special case the tumor suppressors miR-200b and miR-200c act as promoters of stem-cell properties such as pluripotency and immortality which can be suppressed by retinoic acid. In addition, the tumor suppressor miR-663 was upregulated by retinoic acid in leukemia cells (HL-60) leading to leukemia cell differentiation [368]. By the way, miR-10a was downregulated in these HL-60 leukemia cells after treatment with retinoic acid [368]. In glioblastoma cells, retinoic acid enhanced the anticancer effects of transfected miR-124-3p by formation of gap junctions and simplified intercellular transfer of miR-142-3p [369]. In addition, retinoic acid induced glioma cell death by induction of miR-302b leading to suppression of the transcriptional glioma growth regulator E2F3 [370]. Retinoids are derived from carotenoids and lycopene ([Fig. 8](#)) features an interesting carotenoid antioxidant from tomatoes that inhibited tumor growth [371]. In prostate cancer (PC3 cells), lycopene revealed growth inhibition and apoptosis induction via upregulation of let-7f-1 associated with suppression of Akt2 (let-7f-1 target) [372].

![Fig. 8. Chemical structures of lipophilic vitamins and of their derivatives.](#)
Vitamin D and its active metabolite 1,25-dihydroxyvitamin D$_3$ (1,25-D, Fig. 8) are essential natural 9,10-seco-steroids that bind to the vitamin D receptor (VDR) and, thus, modulate various signaling pathways leading to cell cycle arrest (G0/G1), apoptosis and cell differentiation [373]. 1,25-D induced miR-22 expression in colon cancer cells (SW480-ADH, HCT-116) and suppressed target genes such as NELL2, OGN, HRNPH1, RERE and NAF1 with anti-proliferative and anti-migratory effects of 1,25-dihydroxyvitamin D$_3$ [374]. On the other hand, 1,25-D inhibited ArA-induced apoptosis of acute myeloid leukemia cells by induction of miR-32 via Bim [375]. 1,25-D increased miR-627 expression in colon cancer models associated with suppressed JMJ1D1A (a histone demethylase) and growth and differentiation factor 15 leading to colon tumor growth inhibition [376]. The tumor suppressors miR-22, miR-296-3p and miR-498 were induced by 1,25-D in cervical cancer cells (SiHa) accompanied by increased Dicer expression [377]. Dicer expression was increased by 1,25-D because of the vitamin D response element in the Dicer promoter [377]. In addition, the tumor suppressor let-7a-2 was induced by 1,25-D in lung cancer cells (A549), while the tumor suppressors miR-100 and miR-125b were upregulated by 1,25-D in prostate cancer cells [378,379]. However, in MCF-7 breast cancer cells, miR-125b acted as a repressor for VDR and, thus, reduced resistance to 1,25-D via reduced levels of VDR [380]. In human myeloid leukemia cells, 1,25-D suppressed miR-181a and miR-181b leading to cell cycle arrest by upregulation of p27$^{kip1}$ and p21$^{cip1}$ [381]. In addition, down-regulation of the miR-17–92 cluster contributed to 1,25-D anti-cancer activity in NSCLC cells [382]. 1,25-D also down-regulated miR-15a, miR-20b, and miR-181C in HUVECs (human umbilical vein endothelial cells) that contributed to the anti-angiogenic activity of vitamin D [383].

Tocopherol (vitamin E, Fig. 8) is a natural 6-chromanol with an isoprenoid side-chain that possesses antioxidant properties [384]. Vitamin E deficiency led to decreased levels of miR-122a and miR-125b (i.e., microRNAs involved in lipid metabolism, cancer and inflammation) in the liver of rats [385]. Downregulated miR-122a and miR-125b were observed from various cancer types and it is assumed that induction of these miRNAs contributes to the anti-cancer effects of tocopherol [385]. Tocotrienols are closely related to tocopherol and exhibited apoptosis induction via inhibition of signaling pathways such as PI3K/Akt and NF-$\kappa$B [386]. In non-small cell lung cancer cells, delta-tocotrienol (Fig. 8) increased the expression of the tumor suppressor miR-34a leading to inhibition of Notch-1 signaling [387]. Delta-tocotrienol-induced expression of miR-34a suppressed the expression of Notch-1 and of its downstream factors (Hes-1, Cyclin-D1, Survivin, Bcl-2) associated with lung tumor cell growth inhibition, apoptosis induction and inhibition of lung cancer cell invasion [387]. Tocotrienol is a structurally related ubiquinone derivative of the camphor tree mushroom Antrodia camphorata which is applied in TCM for the treatment of several diseases (Fig. 8) [388]. Tocotrienol inhibited cell growth of hepatocellular carcinoma cell lines via AMPK (AMP-activated protein kinase) activation and miTOR inhibition [389]. In non-small cell lung cancer cells, antroquinonol revealed anti-proliferative activity and suppressed the expression of Bcl-2, PI3K and mTOR proteins [390]. Seven microRNAs (miR-15a, miR-18a, miR-2861, miR-302b, miR-382, miR-487a, miR-760) were upregulated in A549 lung cancer cells treated with antroquinonol, while twelve miRNAs were downregulated (miR-10a, miR-135a, miR-299–3p, miR-3126–5p, miR-3153, miR-411, miR-4321, miR-486–5p, miR-505, miR-598, miR-601, miR-939) after antroquinonol treatment [390]. A list of microRNAs regulated by terpenoidal vitamins is presented in Table 12.

### 4. Conclusions

Various natural phenolic and terpenoidal compounds of known anticancer activity exerted their anticancer activity via regulation of microRNAs involved in proliferation, cell death and differentiation, angiogenesis and metastasis formation. Quite a few of these natural compounds (e.g., curcumin, boswellic acid, etc.) have shown low toxicity both in animal studies and in clinical trials and appear to be suitable additives to conventional cancer therapies. In addition, the sensitivity and resistance of cancer cells to approved phenolic and terpenoidal anticancer agents such as doxorubicin, etoposide and taxol include modified expression of tumor suppressor and oncogenic miRNAs. A detailed understanding of the miRNA regulation by natural phenols and terpenes will provide essential information for improved therapy regimens including combination therapies with approved anticancer drugs or other conventional therapies associated with improved prognoses, reduced side-effects, increased quality of life of cancer patients, and breach or prevention of drug resistance.

### References

[1] S.K. Srivastava, S. Arora, C. Avrett, S. Singh, A. Singh, Modulation of micro-RNAs by phytochemicals in cancer: underlying mechanisms and translational significance, Biomed. Res. Int. 2015 (2015). Article ID 848710.
[2] D.J. Guarnieri, R.J. DiLeone, MicroRNAs: a new class of gene regulators, Ann. Med. 40 (2008) 197–208.
[3] H.C. Jeong, E.K. Kim, J.H. Lee, H.N. Yoo, J.K. Kim, Aberrant expression of let-7a miRNA in the blood of non-small cell lung cancer patients, Mol. Med. Rep. 4 (2011) 383–387.
[4] R. Mallick, S.K. Patnaik, S. Yendamuri, Micro RNAs and lung cancer: biology and applications in diagnosis and prognosis, J. Carcinog. 9 (2010) 8.
[5] S.K. Patnaik, R. Mallick, S. Yendamuri, Detection of microRNAs in dried serum blots, Anal. Biochem. 407 (2010) 147–149.
[6] F. Rothé, M. Ignatadis, C. Chaboteaux, B. Haibe-Kains, N. Khodoudi, S. Majaj, B. Badran, H. Fayad-Kazan, C. Desmedt, A.L. Harris, M. Piccart, C. Sotiriou, Global microRNA expression profiling identifies miR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer, PLoS One 6 (2011) e20980.
MRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors, PLoS One 6 (2011) e16915.

[8] W. Huang-Vertesi, H.-P. Chang, P.-C. Wei, C.-Y. Yang, C.-K. Huang, W.-H. Kuo, J.-Y. Shew, K.-J. Chang, E.Y.-P. Lee, W.-H. Lee, miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenes and hypoxia resistance via down-regulation of E-cadherin and REDD1, Oncogene 30 (2011) 5051–5063.

[9] Y. Shimosita, M. Zabala, R.W. Cho, N. Lobo, P. Dalbera, D. Qian, M. Diehn, H. Liu, S.P. Panula, E. Chiao, F.M. Dirbas, G. Somlo, R.A. Perera, K. Lao, M.F. Clarke, Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells, Cell 138 (2009) 592–603.

[10] P.A. Gregory, B.T. Popko, R.P. Ketting, G.J. Hannon, Processing of microRNAs by the microprocessor complex, Nature 434 (2005) 231–236.

[11] E. Lund, S. Guttinger, A. Calado, J.E. Dahlberg, U. Kutay, Nuclear export of miRNA precursors, Science 303 (2004) 95–98.

[12] Y. Zeng, E.J. Wagner, B.R. Cullen, Both natural and designed microRNAs can interact with the expressed mRNAs when expressed in human cells, Mol. Cell 9 (2002) 1327–1333.

[13] G. Hutvagner, J. Mclachlan, A.E. Pasquinelli, E. Bhatia, T. Tuschl, BCL2, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13944–13949.

[14] S.M. Johnson, H. Grosshans, J. Shingara, M. Byrom, R. Jarvis, A. Cheng, et al., MiR-15 and miR-16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 19397–19402.

[15] D. Liu, C. Liu, X. Wang, S. Ingvarsson, H. Chen, MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression, Cancer Epigenetics 5 (2014) 739–745.

[16] G. di Leva, M. Garofolo, C.M. Croce, MicroRNAs in cancer, Ann. Rev. Pathol. 9 (2014) 265–284.

[17] Y. Lee, M. Kim, J. Han, K.-H. Yeom, S. Lee, S.H. Baek, V.N. Kim, MicroRNA genes are transcribed by RNA polymerase II, EMBO J. 21 (2002) 4051–4060.

[18] P.A. Gregori, I.C. Linsley, Expression profiling reveals off-target gene regulation by RNAi, Nat. Biotechnol. 21 (2003) 635–637.

[19] B. Zhang, X. Pan, G.P. Cobb, T.A. Anderson, microRNAs as oncogenes and tumor suppressors, Cancer Cell 13 (2008) 265–276.

[20] J.A. Chan, A.M. Krichevsky, K.S. Kosik, MicroRNA-21 is an antiapoptotic factor that promotes neuronal survival, J. Neurosci. 27 (2007) 1028–1037.
P. Zhang, H. Bai, G. Liu, H. Wang, F. Chen, B. Zhang, P. Zeng, C. Wu, C. Peng, Y. Chen, M.S. Zaman, G. Deng, S. Majid, S. Saini, J. Liu, Y. Tanaka, R. Dahiya, Genistein cell growth by targeting miR-34a and oncogenic HOTAR, PLoS One 8 (2013) e73072.

T. Chiyomaru, S. Yamamura, S. Fukuhara, H. Yoshino, T. Kinoshita, S. Majid, S. Saini, I. Chang, Y. Tanaka, H. Enokida, N. Seki, M. Nakagawa, R. Dahiya, Genistein regulates cell growth by targeting miR-34a and oncogenic HOTAR, PLoS One 8 (2013) e58929.

S. Majid, A.A. Dar, S. Saini, Y. Chen, V. Sharyiari, J. Liu, M.S. Zaman, H. Hirata, S. Yamamura, K. Ueno, Y. Tanaka, R. Dahiya, Regulation of minichromosome maintenance gene family by MicroRNA-1296 and genistein in prostate cancer, Cancer Res. 70 (2010) 2809–2818.

N. Rabiau, H.-K. Tiraf, M. Adjakoy, R. Bosivel, L. Guy, L. Fontana, Y.-J. Bignon, D.J. Bernard-Gallon, miRNAs differentially expressed in prostate cancer cell lines after soy treatment. Vivo 25 (2011) 917–922.

J. Xia, Q. Duan, A. Ahmad, B. Bao, S. Banerjee, Y. Shi, J. Ma, J. Geng, Z. Chen, K.M. Wahidur Rahman, L. Miele, F.H. Sarkar, Z. Wang, Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells, Curr. Drug Targets 13 (2012) 1750–1756.

Y. Li, T.G. Vandenboom, D. Kong, Z. Wang, S. Ali, P.A. Philip, F.H. Sarkar, Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-mesenchymal transition in genistein-resistant pancreatic cancer cells, Cancer Res. 69 (2009) 6704–6712.

Y. Li, T.G. Vandenboom, Z. Wang, D. Kong, S. Ali, P.A. Philip, F.H. Sarkar, MiR-146a suppresses invasion of pancreatic cancer cells, Cancer Res. 70 (2010) 4965–4975.

C.B. Avci, S.Y. Sulsuer, H.O. Caglar, T. Balci, D. Aygunes, Y. Dodurga, C. Gunduz, Genistein-induced miR-23b expression inhibits the growth of breast cancer cells, Contemp. Oncol. 19 (2015) 32–35.

J. Vaya, P.A. Belinsky, M. Aviam, Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation, Free Radic. Biol. Med. 23 (1997) 302–313.

H.S. Kwon, S.M. Oh, J.K. Kim, Glabridin, a functional compound of liquorice, attenuates colon cancer in mice with dextrin sulphate sodium-induced colitis, Clin. Exp. Immunol. 151 (2008) 165–173.

X.Q. Yu, C.C. Xue, Z.W. Zhou, C.G. Li, Y.M. Du, J. Liang, S.F. Zhou, In vitro and in vivo neuroprotective effect and mechanism of glabridin, a major active component of Glycyrrhiza glabra (licorice), Life Sci. 82 (2008) 68–77.

Y.L. Hsu, Y.Y. Wu, M.F. Hou, E.M. Tsai, J.N. Lee, H.L. Liang, Y.J. Yong, C.H. Hung, P.L. Kuo, Glabridin, an flavan from licorice root, inhibits migration, invasion and angiogenesis of MDA-MB-231 human breast adenocarcinoma cells by inhibiting focal adhesion kinase/Rho signaling pathway, Mol. Nutr. Food Res. 55 (2011) 318–327.

F. Jiang, J. Mu, X. Wang, X. Ye, L. Su, S. Ning, Z. Li, Y. Li, The repressive effect of miR-146a on TGF-beta1-SMAD3 signal pathway is involved in the glabridin-induced inhibition of the cancer stem cells-like properties in hepatocellular carcinoma cells, PLoS One 9 (2014) e96698.

F. Jiang, Y. Li, C. Hu, M. Zhou, X. Wang, L. Su, S. Ning, Z. Li, Glabridin inhibits cancer stem cell-like properties of human breast cancer cells: an epigenetic mechanism of miR-146a by inhibiting PTPN6 expression, Oncol. Lett. 13 (2017) 4519–4527.

J. Mu, S. Ning, X. Wang, L. Si, F. Jiang, Y. Li, Z. Li, The repressive effect of miR-520a on NF-kB/IL-6/STAT-3 signal involved in the glabridin-induced anti-angiogenesis in human breast cancer cells, RSC Adv. 5 (2015) 34257–34264.

M.C. Zimmermann, B.S. Beckman, L.V. Rhodes, M.E. Burow, Glyceollin I, a novel antiestrogenic phytoalexin from Glycine max (soybean) isolated, structure elucidation and antioxidative capacity toward LDL oxidation, J. Agric. Food Chem. 53 (2005) 5042–5049.

M. Saini, H. Hirata, K. Ueno, S. Yamamura, S. Fukuhara, H. Enokida, K. Singh, Y. Tanaka, Z.L. Tabatabai, R. Dahiya, Up-regulation of miR-21 correlates with lower kidney cancer survival, PLoS One 7 (2012) e31060.

M.J. Saini, S. Thammanna, Y. Sharyiari, T. Chiyomaru, G. Deng, S. Saini, S. Majid, I. Chang, H. Hirata, K. Ueno, S. Yamamura, K. Singh, Y. Tanaka, Z.L. Tabatabai, R. Dahiya, Up-regulation of microRNA-21 correlates with lower kidney cancer 3-year survival, Cancer Lett. 327 (2013) 235–240.

A. Ahmad, S.H. Sarkar, B. Bitar, S. Ali, A. Aboukameel, S. Sethi, Y. Li, B. Bao, D. Kong, S. Banerjee, S.B. Padhye, F.H. Sarkar, Genistein regulates EMT and Wnt signalling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells, Mol. Cancer Ther. 11 (2012) 2193–2201.

F.H. Sarkar, Y. Li, Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics, Cancer Treat. Rev. 35 (2009) 597–607.

M.S. Zaman, V. Sharyiari, G. Deng, S. Thammanna, S. Saini, S. Majid, I. Chang, H. Hirata, K. Ueno, S. Yamamura, K. Singh, Y. Tanaka, Z.L. Tabatabai, R. Dahiya, Up-regulation of microRNA-21 correlates with lower kidney cancer 3-year survival, PLoS One 7 (2012) e31060.

M.S. Zaman, S. Thammanna, V. Sharyiari, T. Chiyomaru, G. Deng, S. Saini, S. Majid, S. Fukuhara, I. Chang, S. Arora, H. Enokida, K. Singh, Y. Tanaka, Z.L. Tabatabai, R. Dahiya, Up-regulation of miR-21 correlates with lower kidney cancer 3-year survival, PLoS One 7 (2012) e50203.

H. Hirata, K. Ueno, K. Nakajima, Z.L. Tabatabai, Y. Hinoda, N. Ishii, R. Dahiya, Genistein downregulates onco-miR-126 and miR-100 and inhibits Wnt-signaling in renal cancer cells, Br. J. Cancer 108 (2013) 2070–2078.

H. Hirata, Y. Hinoda, V. Sharyiari, G. Deng, Y. Tanaka, Z.L. Tabatabai, R. Dahiya, Genistein downregulates onco-miR-126 and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells, Br. J. Cancer 110 (2014) 1645–1654.

Q. Sun, R. Cong, H. Yan, H. Gu, Y. Zeng, N. Liu, J. Chen, B. Wang, Genistein inhibits growth of human uveal melanoma cells and affects microRNA-27a by targeting gene expression, Oncol. Lett. 22 (2016) 563–570.

L. Xue, J. Xiang, J. Shen, X. Zou, S. Zhai, Y. Yin, P. Li, X. Wang, Q. Sun, Oncogenic microRNA-27a is a target for genistein in ovarian cancer cells, Anti-Cancer Agents Med. Chem. 13 (2013) 1126–1132.

J. Xie, L. Cheng, C. Mei, J. Ma, Y. Shi, F. Zeng, Z. Wang, Z. Genestein inhibits cell growth and invasion through regulation of miR-27a in pancreatic cancer cells, Curr. Pharm. Des. 20 (2014) 5348–5353.

T. Chiyomaru, S. Yamamura, M.S. Zaman, S. Majid, G. Deng, V. Sharyiari, H. Hirata, K. Ueno, S. Yamamura, K. Singh, Y. Tanaka, Z.L. Tabatabai, R. Dahiya, M. Nakagawa, R. Dahiya, Genistein suppresses prostate cancer growth through inhibition of oncogenic MicroRNA151, PLoS One 7 (2012) e43812.

Y. Chen, M.S. Zaman, G. Deng, S. Majid, S. Saini, I. Liu, Y. Tanaka, R. Dahiya, MicroRNAs: 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer, Cancer Prev. Res. 4 (2011) 76–86.

J. Ma, L. Cheng, H. Liu, J. Zhang, Y. Shi, F. Zeng, L. Miele, F.H. Sarkar, J. Xia, Z. Wang, Genistein down-regulates miR-223 expression in pancreatic cancer cells, Curr. Drug Targets 13 (2011) 1150–1156.
M. Ohno, C. Shibata, T. Kishikawa, T. Yoshikawa, A. Takata, K. Kojima, T.K. Lam, S. Shao, Y. Zhao, F. Marincola, A. Pesatori, P.A. Bertazzi, M. Appari, K. Babu, A. Kaczorowski, W. Gross, I. Herr, Sulphoraphane, D. Patel, S. Shukla, S. Gupta, Apigenin and cancer chemoprevention: progression and potential, Int. J. Oncol. 30 (2007) 233–245.

M. Chakrabarti, N.L. Banki, S.K. Ray, miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways, Biochem. Biophys. Res. Commun. 388 (2009) 802–807.

S.-C. Chao, S.-C. Huang, D.-N. Hu, H.-Y. Lin, Subtoxic levels of apigenin inhibit expression and secretion of VEGF by uveal melanoma cells via inhibition of ERK1/2 and PI3K/Akt pathways, Evidence-Based Complement, Altern. Med. 2013 (2013). Article ID 817674.

S. Shukla, S. Gupta, Apigenin: a promising molecule for cancer prevention, Pharm. Res. 27 (2010) 962–978.

D. Patel, S. Shukla, S. Gupta, Apigenin and cancer chemoprevention: progress, potential and promise, Int. J. Oncol. 34 (2009) 115–126.

M. Chakrabarti, N.L. Banki, S.K. Ray, miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways, Biochem. Biophys. Res. Commun. 388 (2009) 802–807.

S.-C. Chao, S.-C. Huang, D.-N. Hu, H.-Y. Lin, Subtoxic levels of apigenin inhibit expression and secretion of VEGF by uveal melanoma cells via inhibition of ERK1/2 and PI3K/Akt pathways, Evidence-Based Complement, Altern. Med. 2013 (2013). Article ID 817674.

S. Shukla, S. Gupta, Apigenin: a promising molecule for cancer prevention, Pharm. Res. 27 (2010) 962–978.

D. Patel, S. Shukla, S. Gupta, Apigenin and cancer chemoprevention: progress, potential and promise, Int. J. Oncol. 30 (2007) 233–245.

M. Chakrabarti, N.L. Banki, S.K. Ray, miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways, Biochem. Biophys. Res. Commun. 388 (2009) 802–807.

S.-C. Chao, S.-C. Huang, D.-N. Hu, H.-Y. Lin, Subtoxic levels of apigenin inhibit expression and secretion of VEGF by uveal melanoma cells via inhibition of ERK1/2 and PI3K/Akt pathways, Evidence-Based Complement, Altern. Med. 2013 (2013). Article ID 817674.

S. Shukla, S. Gupta, Apigenin: a promising molecule for cancer prevention, Pharm. Res. 27 (2010) 962–978.

D. Patel, S. Shukla, S. Gupta, Apigenin and cancer chemoprevention: progress, potential and promise, Int. J. Oncol. 30 (2007) 233–245.

M. Chakrabarti, N.L. Banki, S.K. Ray, miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways, Biochem. Biophys. Res. Commun. 388 (2009) 802–807.

S.-C. Chao, S.-C. Huang, D.-N. Hu, H.-Y. Lin, Subtoxic levels of apigenin inhibit expression and secretion of VEGF by uveal melanoma cells via inhibition of ERK1/2 and PI3K/Akt pathways, Evidence-Based Complement, Altern. Med. 2013 (2013). Article ID 817674.

S. Shukla, S. Gupta, Apigenin: a promising molecule for cancer prevention, Pharm. Res. 27 (2010) 962–978.

D. Patel, S. Shukla, S. Gupta, Apigenin and cancer chemoprevention: progress, potential and promise, Int. J. Oncol. 30 (2007) 233–245.

M. Chakrabarti, N.L. Banki, S.K. Ray, miR-138 overexpression is more powerful than hTERT knockdown to potentiate apigenin for apoptosis in neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways, Biochem. Biophys. Res. Commun. 388 (2009) 802–807.

S.-C. Chao, S.-C. Huang, D.-N. Hu, H.-Y. Lin, Subtoxic levels of apigenin inhibit expression and secretion of VEGF by uveal melanoma cells via inhibition of ERK1/2 and PI3K/Akt pathways, Evidence-Based Complement, Altern. Med. 2013 (2013). Article ID 817674.

S. Shukla, S. Gupta, Apigenin: a promising molecule for cancer prevention, Pharm. Res. 27 (2010) 962–978.
D. Edwardson, S. Chewchuk, A.M. Parissenti, Resistance to Anthracyclines

W.-H. Liu, L.-S. Chang, Suppression of Akt/Foxp3-mediated miR-183

J. Long, Z. Ji, K. Jiang, Z. Wang, G. Meng, MiR-193b modulates resistance to

Z. Zhao, R. Li, S. Sha, Q. Wang, W. Mao, T. Liu, Targeting HER3 with miR-450b-

H. He, W. Tian, H. Chen, Y. Deng, MicroRNA-101 sensitizes hepatocellular

S. Bae, E. Lee, H.J. Cha, K. Kim, Y. Yoon, H. Lee, J. Kim, Y.J. Kim, H.G. Lee,

M.A. Seyed, I. Jantan, S.N.A. Bukhari, K. Vijayaraghavan, A comprehensive

E. Venkatadri, T. Muni, A.K.V. Iyer, J.S. Yakisich, N. Azad, Role of apoptosis-

Combining miR-10b-targeted nanotherapy with low-dose doxorubicin

N. Barteneva, V. Petkova, P. Pantazopoulos, A. Tena, A. Moore, Z. Medarova,

L.M. Pfeffer, J. Wu, Z.-H. Wu, Induction of miRNA-181a by genotoxic treat-

J. Hua, Y. He, Y. Xu, X. Jiang, W. Ye, Y. Pan, Emodin prevents intima thickness

B. Zhou, H. Yi, J. Tan, Y. Wue, G. Liu, Z. Qiu, Anti-proliferative effects of

A.B. Shirode, P. Kovvuru, S.V. Chittur, S.M. Henning, et al., Antiproliferative

N. Banerjee, T. Soltat, S. Safe, S.U. Mertens-Talcott, Cytotoxicity of pome-

K. Hagiwara, L. Gailhouste, K. Yasukawa, N. Kosaka, T. Ochiya, A robust

K. Shi, M. Shi, J. Li, Y. Wang, Y. Jin, Y. Weng, D. Wu, MicroRNA-522 reverses drug resistance of doxorubicin-

J. Zheng, J. Tan, Y. Yue, G. Liu, Z. Qiu, Anti-proliferative effects of polyphenols from pomegranate rind (Punica granatum L.) on EJ bladder

H. He, W. Tian, H. Chen, Y. Deng, MicroRNA-101 sensitizes hepatocellular carcinoma cells to doxorubicin-induced apoptosis via targeting Mcl-1, Mol. Cell. Biol. 13 (2013) 1313–1313.

G. Wu, Ellagitannin (BJA3121), an antiproliferative natural polyphenol compound, can regulate the expression of miRNAs in HepG2 cancer cells, Phytoser. Res. 23 (2009) 887–892.

Y.-X. Wen, S.-Y. Wu, Z.-Q. Liu, J.-Z. Jiang, G.-F. Wang, Z.-H. Jiang, S.-G. Wu, Elagatinnin (BJA3121), an antiproliferative natural polyphenol compound, can regulate the expression of miRNAs in HepG2 cancer cells, Phytoser. Res. 23 (2009) 778–784.

R. Ai, S. Wu, X. Wen, W. Xu, L. Liu, R. Jia, S. Cao, 1,3,4-tri-O-galloyl-6-O-cafeoyl-

Z. Li, J. Xing, W. Ji, J. Chen, Y. Guo, J. Zhang, miR-193b modulates resistance to doxorubicin in human breast cancer cells by downregulating miR-15b and inhibition of MMP-9 expression, Oncol. Rep. 33 (2015) 2815–2820.

F. Lombro, N. Menendez, J.A. Salas, C. Mendez, The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives, Appl. Microbiol. Biotechnol. 73 (2006) 71–71.

N. Bianchi, C. Zuccato, I. Lampreonti, M. Borgatti, Expression of miR-210 during erythroid differentiation and induction of gamma-globin gene expression, BMP Rep. 42 (2009) 493–499.

Z.H. Jiang, Y. Hisiro, H. Iwara, S. Sakamoto, T. Tanaka, I. Kouno, Caffeoyl, coumaroyl, galloyl, and hexahydroxydiphenoyl glucosides from Balanopopha japonica, Chem. Pharm. Bull. 49 (2001) 887–902.

X.-Y. Wen, S.-Y. Wu, Z.-Q. Liu, J.-Z. Jiang, G.-F. Wang, Z.-H. Jiang, S.-G. Wu, Elagatinnin (BJA3121), an antiproliferative natural polyphenol compound, can regulate the expression of miRNAs in HepG2 cancer cells, Phytoser. Res. 23 (2009) 778–784.

M. Nüsslein-Talcott, S. Safe, S.U. Mertens-Talcott, Cytotoxicity of pomegranate polyphenolics in breast cancer cells in vitro and vivo: potential role of miRNA-27a and miR-155 in cell survival and inflammation, Breast Cancer Res. Treat. 136 (2012) 21–34.

R. Chen, H. Shi, Z. Yang, H. Wang, D. Gao, J. Li, J. Zhang, miR-193b suppresses the Warburg effect in human breast cancer cells, Mol. Cancer Ther. 7 (2008) 2152–2159.

E. Lombo, N. Menendez, J.A. Salas, C. Mendez, The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives, Appl. Microbiol. Biotechnol. 73 (2006) 71–71.

A. Vayas, K. Syeda, A. Ahmad, S. Padhye, F.H. Sarkar, Perspectives on medicinal properties of mangiferin, Mini-Rev. Med. Chem. 12 (2012) 412–425.

M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.

H. Chiu, M. Nuzzo, T. Tommasi, G. Cellai, G. Gerli, P. Santoli, G. Carlei, Valproic acid and miR-21-targeted short interfering RNA synergistically inhibit growth and reverse multidrug resistance in human breast cancer cells, Mol. Cancer Ther. 11 (2012) 2804–2814.
E. Guerriero, A. Sorice, F. Capone, S. Costantini, P. Palladino, M. D'Ischia, L. Wang, M. Lu, M. Yi, L. Chen, J. Shen, Z. Li, L. Li, Y. Yang, J. Zhang, Y. Li, Caffeic Y. Li, F. Jiang, L. Chen, Y. Yang, S. Cao, Y. Ye, X. Wang, J. Mu, Z. Li, L. Li, P.N. Alexandrov, P. Dua, J.M. Hill, S. Bhattacharjee, Y. Zhao, et al., MicroRNA S. Han, S. Yang, Z. Cai, D. Pan, Z. Li, Z. Huang, P. Zhang, H. Zhu, L. Lei, W. Wang, A.B. Kunnumakkara, A.S. Nair, B. Sung, M.K. Pandey, B.B. Aggarwal, Boswellic J.M. Henwood, R.N. Brogden, Etoposide. A review of its pharmacodynamics E.G. Seviour, V. Sehgal, Y. Lu, Z. Luo, T. Moss, F. Zhang, S.M. Hill, W. Liu, S.N. Maiti, B. Biersack / Non-coding RNA Research 1 (2016) 12
M.C. Wani, H.L. Taylor, M.E. Wall, P. Coggan, A.T. McPhail, Plant antitumor agents. VI. The isolation and structure of Taxol. J. Am. Chem. Soc. 93 (1971) 2031–2037.

P.B. Schiff, S.B. Horwitz, Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U. S. A. 77 (1980) 1561–1565.

N. Chen, H.S. Chen, Y. Xiong, D.C. Marchion, P.L. Judson, A. Hakam, J.A. Casadevall, Deacetylation of Taxus-Permuwth-1,14-dimethyllacone by plant cultures. J. Nat. Prod. 70 (2007) 208–216.

X. Dai, W. Fan, Y. Wang, L. Huang, Y. Jiang, L. Shi, D. McKinley, W. Tan, C. Tan, Combined delivery of let-7b micro-RNA and paclitaxel via biodegradable nanoassemblies for the treatment of KRAS mutant cancer. Mol. Pharm. 13 (2016) 520–531.

B. Biersack / Non-coding RNA Research 1 (2016) 12–34

10.1007/s13277-016-5066-2.
[352] R. Schobert, B. Biersack, A. Dietrich, A. Grotenmeier, T. Müller, B. Kalinowski, S. Knauer, W. Voigt, R. Paschke, Monoterpenes as drug shuffles: cytoxic (6-aminomethylxinoctinate)-dichlorophenyl(II) complexes with potential to overcome cisplatin resistance, J. Med. Chem. 50 (2007) 1288–1293.

[353] D. Worthen, G. Gho sheh, P. Crooks, The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L, Anticancer Res. 18 (1998) 1527–1532.

[354] W. Reindl, J. Yuan, A. Kramer, K. Strebehrdt, T. Berg. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions, Chem. Biol. 15 (2008) 459–466.

[355] S. Bhattacharya, M. Abir, P. Patra, S. Mukherjee, S. Ghosh, M. Mazumdar, S. Chattopadhyay, T. Das, D. Chattopadhyay, A. Adhikary, PEGylated-thy moquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytostatic actors polymerization through miR-34A, Biomaterials 51 (2015) 91–107.

[356] J.T. Li, W. He, S.S. Song, W. Wei, Paeoni influin inhibited the tumor invasion and metastasis in human hepatocellular carcinoma cells, Bratisl. Leky. 115 (2014) 427–433.

[357] W. Li, Z. Qi, Z. Wei, S. Liu, P. Wang, Y. Chen, Y. Zhao, Paeoni influin inhibits proliferation and induces apoptosis of human glioma cells via microRNA-16 upregulation and matrix metalloproteinase-9 downregulation, Mol. Med. Rep. 12 (2015) 2735–2740.

[358] P. V. Cristi, P. Messina, M. Ciocci, D. Masilli, L. Di Cesare, C. Poli, G. Gualandi, L. Mercuri, A. Baiocchi, G. P. Crocco, The expression of miRNAs and miRNA expression, PLoS One 10 (2015) e0132566.

[359] H. Guan, C. Liu, Z. Chen, L. Wang, C. Li, J. Zhao, Y. Yu, F. Zhang, W. Chen, A. Jiang, 1,25-Dihydroxyvitamin D3 up-regulates expression of hasa-let-7a-2 through the interaction of VDR/NR1D1 in human cancer A549 cells. Gene 522 (2013) 142–146.

[360] A.A. Giangreco, A. Vaishnav, D. Wagner, A. Finelli, N. Flesher, T. van der Kwaast, R. Vieth, L. Nonn, Tumor suppressor microRNAs, miR-100 and miR-125b, are regulated by 1,25-dihydroxyvitamin D in primary prostate cells and in patient tissue, Cancer Prev. Res. 6 (2013) 483–494.

[361] T. Mohri, M. Nakajima, S. Takagi, S. Komagata, T. Yoko, MicroRNA regulates human vitamin D receptor, Int. J. Cancer 125 (2009) 1328–1333.

[362] X. Wang, E. Goeck, C. Liu, G.P. Studzinski, MicroRNA181 regulates the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3, Cell Cycle 8 (2009) 736–741.

[363] R. Borkowski, L. Du, Z. Zhao, E. McMillan, A. Kosti, C.-R. Yang, M. Suraokar, L. Wistuba, A.F. Gazdar, J.D. Minna, M.A. White, A. Pertsinides, Genetic mutation of p53 and suppression of the miR-17–92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D signaling, Cancer Res. 75 (2014) 666–675.

[364] T. Zittman-Gal, J. Green, M. Pasmank-Chor, E. Golan, J. Bernheim, S. Bencherit, Vitamin D manipulates miR-181c, miR-20b and miR-15a in human umbilical vein endothelial cells exposed to a diabetic-like environment, Cardiovasc. Diabetol. 13 (2014) 8.

[365] G. Rimbach, J. Moehring, P. Huebbe, J.K. Lodge, Gene-regulatory activity of α-tocopherol, Molecules 15 (2010) 1746–1761.

[366] S. Gaedicke, X. Zhang, C. Schmelzer, Y. Lu, F. Doering, J. Frank, G. Rimbach, Vitamin E dependent microRNA regulation in rat liver, FEBS Lett. 582 (2008) 3542–3546.

[367] A.B. Shirode, P.W. Sylvester, Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression of NFκB and NFKB signaling, Biochem. Pharmacol. 64 (2010) 327–332.

[368] X.J. Z. Wang, A. Geamanu, A. Goja, F.H. Sarkar, S.V. Gupta, Delta-tocotrienol suppresses Notch-1 pathway by upregulating miR-34a in non-small cell lung cancer cells, Int. J. Cancer 131 (2012) 2677–2688.

[369] C.C. Chen, Y.I. Shiao, B.D. Lin, Y.Y. Shao, M.N. Lai, C.C. Lin, L.T. Ng, Y.H. Xuo, Neuroprotective deribings from the fruiting body of Antrodia camphorata, J. Nat. Prod. 69 (2006) 689–691.

[370] P.C. Jiang, S.C. Lin, S.L. Pan, K.C. Tsai, M.T. Kuo, W.C. Wen, P. Chen, J.H. Guh, Antiquinonin displays anticancer potential against human hepa tococellular carcinoma cells: a crucial role of AMPK and mTOR pathways, Biochem. Pharmacol. 79 (2010) 162–171.

[371] V.B. Kumar, T.-C. Yuan, J.-W. Liou, C.-J. Yang, P.-J. Sung, C.-F. Weng, Antiquinonin inhibits NSCLC proliferation by altering P38/MAPK pathways and miRNA expression profiles, Mut. Res. 707 (2011) 42–52.